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Depression is a common mental health comorbidity in cancer diagnoses, affecting 8-24% 
of cancer patients. Despite the high prevalence of depression among cancer patients, it is 
often unrecognized and untreated, thereby representing an enormous psychological 
distress source among the cancer patient population. The purpose of this study was to 
explore and establish the factors that predict depression screening among cancer patients 
in the ambulatory care setting in the United States. The health belief model guided the 
study. Secondary data from the National Ambulatory Medical Care Survey were analyzed 
to evaluate the predictors of depression screening in patients diagnosed with cancer. The 
logistic regression model was used to analyze the data and test whether the independent 
variables predicted depression screening among cancer patients. The study result showed 
a low depression screening rate of 3.8% among cancer patients. Patient age, physician 
specialty, and geographic region of the physician visit were found to be statistically 
significant predictors of receipt of depression screening among cancer patients attending 
ambulatory care settings. However, when all of the independent variables were controlled 
for in the logistic model, the gender variable was no longer a statistically significant 
predictor of depression screening, thereby indicating a potential confounding effect. 
Overall, the current study may contribute positively to society by stimulating new 
approaches to recognizing and managing patients with comorbid conditions and 
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Chapter 1: Introduction to the Study  
Background 
Cancer continues to be one of the leading causes of death in the United States, 
second only to cardiovascular disease (D’Souza et al., 2019). Comorbidity with cancer is 
associated with increased cancer-specific mortality and other causes of mortality (Pule et 
al., 2019). Specifically, there is abundant evidence that for cancer patients, an additional 
diagnosis of mental illness, including depression, reduces survivability (Koroukian & 
Sajatovic, 2017; Zhu et al., 2017). In addition to the excess cancer mortality seen in 
people with depression, cancer, and depression, comorbidity prevalence also continues to 
increase (Krebber et al., 2014). The literature shows considerable variation in prevalence 
estimates of comorbid depression and cancer. Such estimates are partly dependent on the 
methodology used to define depression and the population (Michael, 2007). Walker and 
colleagues used strict eligibility criteria in selecting articles to address the limitations of 
previous reviews and explore the prevalence of depression in adults with cancer. The 
authors reported a prevalence of 5-16% in outpatients, 4-14% in inpatients, 4-11% in 
mixed outpatient and inpatient samples, and 7-49% in palliative care (Walker et al., 
2013). Other authors have reported similar estimates (Wagner et al., 2017). However, still 
other authors have reported higher prevalence rates, such as 21.5% in a Taiwanese cancer 
inpatient population (Tu et al., 2014) and 56.5% in a Czechoslovakian population 
(Světláková et al., 2019). 
Some authors have estimated the prevalence of depression by cancer type. For 
example, Margari et al. (2016) investigated depression and anxiety among lung cancer 
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patients. The prevalence of depression in Margari et al.’s sample was 21.8%, and the 
prevalence of anxiety was 17.9%. The authors demonstrated a statistically significant 
correlation between depression and hospitalization, with hospitalized patients exhibiting 
almost twice the severe depression rates compared to those not hospitalized. 
Wondimagegnehu et al. (2019) conducted a cross-sectional study of 428 breast cancer 
patients and reported that 1 in every 4 patients had depression.    
Early detection and prompt treatment of depression symptoms among cancer 
patients can reduce patients’ suffering, prevent progression to a major depressive 
disorder, and improve treatment compliance (Howell et al., 2011). Although more 
favorable outcomes have been documented when depression is treated, cases may go 
unrecognized and untreated (Abid et al., 2018). There have been several calls to 
proactively and systematically screen for depression in cancer patients (McNiff et al., 
2008; Riba et al., 2019; Wagner et al., 2013). Several screening tools for depression have 
been developed, some of which have been validated for use in oncology. While screening 
tools used to measure depression in patients with physical illness have generally not 
demonstrated superior clinical use compared to traditional clinical interviews and mental 
status examination, screening instruments can nevertheless be useful in identifying 
patients in need of further assessment (PDQ Supportive and Palliative Care Editorial 
Board, 2019). Screening instruments commonly used for this purpose include the 
Hospital Anxiety and Depression Scale (HADS), the nine-item Patient Health 




Identifying the potential predictors of and risk factors for the development of 
depression in cancer patients could facilitate the prompt identification of patients at risk 
for depression. Several authors have explored such predictors. For example, Wen et al. 
(2019) conducted a systematic literature review to identify the risk factors for depression 
in cancer patients undergoing chemotherapy. Social support, anxiety, perceived stress, 
and self-efficacy were factors that were consistently associated with depression in cancer 
patients. Gender has also been shown to be a variable with a potential effect on the 
diagnosis of depression. Lima et al. (2016) explored the predictor variables for depression 
in 400 adult cancer outpatients attending a specialized cancer hospital. Male gender was 
the only protective factor found against the development of depressive disorder. Female 
gender was found to be a risk factor for both depression and anxiety disorder. Other 
factors explored included previous psychiatric history and marital status, which were risk 
factors for developing an anxiety disorder.  
Although studies have identified predictors of depression screening among the 
general adult population and adult population with chronic disease, no studies have 
systematically explored predictors of depression screening among cancer patients. For 
example, Bhattacharjee et al. (2018) examined national patterns of predictors and trends 
in depression screening among adults without depression in the United States. The 
predictors examined included year, gender, physician specialty, geographic region, and 
time spent with the physician. The national-level depression screening rate was reported 
as 1.4% of all adults studied, and the predictors examined were significantly associated 
with depression screening.  
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There is a tendency for patients with chronic physical conditions such as cancer to 
use mental health services less than those without such conditions. Jolles and colleagues 
(2015) studied whether the presence of chronic physical conditions was associated with 
mental health service use for individuals with depression who visited a primary care 
physician and whether race modified the relationship. Patients who reported at least one 
chronic condition were found to have a 6% decrease in the probability of using a mental 
health service. Race or ethnicity did not contribute to any differences seen in service use. 
Considering the relatively high prevalence of depression among cancer patients and the 
high rate of depression underdiagnosis and treatment, gaining insight into issues 
surrounding screening and cues for identifying depression has public health significance. 
Indeed, recognizing the predictors of depression screening in patients diagnosed with 
cancer can expedite early and prompt diagnosis with the potential for prompt treatment. 
Ultimately, this can improve cancer-related outcomes, including quality of life and 
survivability (Koroukian & Sajatovic, 2017). 
Problem Statement 
Cancer continues to be a leading cause of death in the United States. For example, 
over half a million cancer deaths were expected in the United States in 2020 (American 
Cancer Society, 2020). Despite new and innovative interventions to curb high cancer 
mortality, fatal outcomes are still prevalent. The comorbidity of cancer with chronic 
health conditions is common and has been widely studied and shown to contribute to the 
increased mortality seen among cancer patients (Park et al., 2017). Depression represents 
one of the most frequent mental disorders that occurs comorbidly with cancer (Smith, 
5 
 
2015). Poorer cancer outcomes, including increased cancer mortality, are associated with 
comorbid mental illness (Zhu et al., 2017). With a comorbidity of depression, cancer 
mortality drastically increases (Musuuza et al., 2013). In a cohort study of 244,261 adult 
patients diagnosed with primary cancer, patients with a first-onset mental disorder, 
including mood disorders, were at increased risk of cancer-specific mortality (Zhu et al., 
2017). Therefore, while a cancer diagnosis represents a grave medical condition, 
comorbidity with depression presents an additional burden, making it an even more 
significant public health issue. Depression is associated with a higher level of stress-
related biomarkers (Strawbridge et al., 2017). Similar chemical imbalances have been 
proposed to be a mediating factor in cancer's widespread inflammatory processes 
(Koroukian & Sajatovic, 2017). Therefore, adequate treatment of depression comorbidly 
occurring with cancer may reduce the inflammatory processes seen in cancer 
pathophysiology, potentially impacting the rate of cancer remission, cure, and mortality 
outcomes. 
Early diagnosis and prompt treatment of depression in cancer are associated with 
better cancer outcomes. However, most cases of depression in cancer patients are missed 
by medical professionals for several reasons, including inadequate physician training, 
increased patient load, and limited time to examine patients’ emotional function 
holistically (Popoola & Adewuya, 2012). The adoption of simple screening instruments 
has repeatedly demonstrated effectiveness in identifying depressive symptoms among the 
cancer patient population. Identifying predictors or determinants of depression screening 
can potentially help healthcare providers navigate the process of screening for depression 
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among cancer patients (Harrison et al., 2010). However, there is currently no study that 
has explored the predictors of depression screening among cancer patients. Therefore, 
there is a need for research to examine such potential relationships.   
Previous studies have explored national-level predictors of and trends in 
depression screening among adult populations with or without a depression diagnosis in 
ambulatory care settings (Bhattacharjee et al., 2018; Harrison et al., 2010; Schmitt et al., 
2010). However, no study has examined the predictors of depression screening among 
patients who are diagnosed with cancer. Therefore, this study’s objective was to 
determine the predictors of depression screening among patients with cancer. 
Purpose of Study 
The purpose of this research was to determine and evaluate the predictors of 
depression screening among cancer patients in ambulatory care settings in the United 
States. Therefore, the study explored the factors that predict depression screening for 
cancer patients in ambulatory settings. Sociodemographic factors, such as age, gender, 
and race, as well as other variables such as physician specialty, time spent with the 
physician, and consultation with a mental health provider, were explored as potential 
predictor variables in this study. The outcome variable was depression screening 
(yes/no). A quantitative approach was used to determine if there were any relationships 
between the independent and dependent variables.   
Research Questions and Hypotheses 
RQ1.  Is there an association between consultation with a mental health provider 
and screening for depression among patients with a diagnosis of cancer? 
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Null hypothesis (H0): There is no statistically significant association 
between consultation with a mental health provider and screening 
for depression among patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between consultation with a mental health provider and screening 
for depression among patients with a diagnosis of cancer. 
RQ2.  Is there an association between time spent with the physician and 
screening for depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between time spent with the physician and screening for 
depression among patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between time spent with the physician and screening for 
depression among patients with a diagnosis of cancer. 
RQ3.  Is there an association between gender and screening for depression 
among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between gender and screening for depression among patients with 
a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between gender and screening for depression among patients with 
a diagnosis of cancer. 
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RQ4.  Is there an association between age and screening for depression among 
patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between age and screening for depression among patients with a 
diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant 
association between age and screening for depression among 
patients with a diagnosis of cancer.  
RQ5.  Is there an association between race and screening for depression among 
patients with a diagnosis of cancer?  
Null hypothesis (H0): There is no statistically significant association 
between race and screening for depression among patients with a 
diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between race and screening for depression among patients with a 
diagnosis of cancer. 
RQ6.  Is there an association between physician specialty and screening for 
depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between physician specialty and screening for depression among 
patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
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between physician specialty and screening for depression among 
patients with a diagnosis of cancer. 
Theoretical Framework 
Theories powerfully influence how evidence is collected, analyzed, understood, 
and used, making it practical and scientific to explore theories and make them 
foundational in research development (Alderson, 1998). A useful framework for this 
dissertation was the health belief model (HBM). The HBM posits that “messages will 
achieve optimal behavior change if they successfully target perceived barriers, benefits, 
self-efficacy, and threat” (Jones et al., 2014, p. 566). The key constructs of the HBM 
include risk susceptibility, risk severity, benefits to action, barriers to action, self-
efficacy, and cues to action (Becker, 1974; Champion & Skinner, 2008).  
Knowing the predictors of depression screening among patients with a diagnosis 
of cancer can empower patients, practitioners, and stakeholders to begin seeing risks and 
thereby potentially stimulate behavioral changes. Such behavioral changes may include 
cancer patients seeking mental health consultations even before they are diagnosed with a 
mental condition such as depression. Physicians who take care of cancer patients can 
learn to recognize cues that prompt them to initiate depression screening discussions. 
This idea aligns very well with the concept of value-expectancy, which posits that 
behavior can be understood when the value that an individual places on a particular 
outcome is known as the likelihood (i.e., expectation) that the action will result in the 
desired outcome (Gipson & King, 2012).  
This study determined whether there was an association between screening for 
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depression, the dependent variable, and the independent variables of age, gender, race, 
physician specialty, consultation with a mental health provider, and time spent with 
physicians among adults with a cancer diagnosis. A perceived risk severity and risk 
susceptibility (of a negative cancer outcome complicated by the co-occurrence of 
depression) could motivate patients and their providers to recommend early screening for 
depression. Chapter 2 outlines the historical perspective and operationalization of the key 
concepts of the HBM. 
Based on the HBM, consulting with a mental health provider contributes to risk 
perception (perceived susceptibility) for developing depression (Choudhry et al., 2016). 
Additionally, spending more time with physicians helps one understand the depth of the 
risk (perceived severity) of the various physical, psychological, social, and economic 
complications of depression (Bhattacharjee et al., 2018; Wen et al., 2019). 
Sociodemographic factors such as gender and age can influence the belief that depression 
screening is useful and applicable (perceived benefits) for individuals diagnosed with 
cancer (Bhattacharjee et al., 2018; Wen et al., 2019). There is evidence that race may 
prevent individuals (perceived barriers) from ultimately taking preventive action, 
including undergoing depression screening (Hansotte et al., 2017; Wen et al., 2019). The 
physician’s specialty is an external trigger (cues to action) that may increase the 
possibility of getting screened for depression (Bhattacharjee et al., 2018; Wen et al., 
2019). Given this study’s objective, which was to determine and evaluate the factors that 
can influence screening for depression in ambulatory settings for adults with a cancer 
diagnosis, the HBM was an appropriate theoretical framework for this study. 
11 
 
Nature of the Study 
This study was quantitative and used a cross-sectional design. The study's goal 
was to determine the predictors of depression screening among cancer patients in 
ambulatory settings. Secondary data from the National Ambulatory Medical Care Survey 
(NAMCS), which comprises a national probability sample of visits to the emergency and 
outpatient departments of noninstitutional general and short-stay hospitals, were 
analyzed. The NAMCS data were designed to meet the need for objective, reliable 
information about the provision and use of ambulatory medical care services in the 
United States. The database is open to the public and easily accessed by going to a 
website. The data were collected using surveys that captured physician-patient encounters 
or clinic visits. These encounters could have involved direct or personal interactions 
between patients and their physicians or clinic staff working under the direct supervision 
of a physician. A multistage probability sampling design was employed to collect the 
NAMCS data (National Center for Health Statistics [NCHS], 2015). This involved 
probability samples of primary sampling units (PSUs), physician practices within PSUs, 
and patient visits within practices. The second stage involved a probability sample of 
practicing physicians, and the final stage was the selection of patient visits within the 
annual practices of sample physicians. 
The logistic regression model was used to analyze the data and test whether the 
independent variables predicted the dependent variable. Logistic regression is ideal for 
testing models when there is one nominal and two or more measurement variables 
(Pallant, 2010). As a statistical model, the logistic regression describes the relationship 
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between an independent variable and a binary dependent variable. The independent 
variables could be one or more nominal, ordinal, or interval level independent variables 
(Nick & Campbell, 2007). Therefore, the one dependent variable that I used in the study 
was dichotomized, and the use of logistic regression was justified.   
Definitions 
A concise definition for each of the independent and dependent variables as used 
in this study is provided below:  
Depression: A mood disorder characterized by an experience of persistent 
feelings of sadness, hopelessness, and loss of interest. Depression, as used in the study, 
includes both symptoms of depression and any of the five classifications of a depressive 
disorder by the American Psychiatric Association’s Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5; American Psychiatric Association, 2013). 
Screening: “Screening for diseases is the examination of asymptomatic people to 
classify them as likely or unlikely to have the disease that is the object of screening. 
People who appear likely to have a disease are investigated further to arrive at a final 
diagnosis. Those people who are found to have the disease are then treated” (Morrison, 
1992, p. 3). 
Depression screening: The use of validated and nonvalidated instruments to 
identify asymptomatic people to classify them as likely or unlikely to have depression. 
Mental health provider: This refers to psychologists, counselors, social workers, 
and therapists who provide mental health counseling, including psychiatrists. 
Cancer: A disease whereby a single normal body cell undergoes a genetic or 
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metabolic transformation characterized by an uncontrolled division of abnormal cells in a 
part of the body. The term is used with any body site. 
Time spent with a physician: The amount of time (in minutes) that a physician 
spends with a patient, not including time that the patient spends waiting for an 
appointment or with another type of practitioner (NCHS, 2007). 
Assumptions 
In this study, I attempted to identify the predictor variables for depression 
screening among cancer patients using secondary data collected by the NAMCS. The 
data consisted of surveys administered to patient populations in the ambulatory care 
setting across the United States. One of the assumptions for this study was that the 
respondents answered the survey questions as truthfully as possible. The NAMCS used 
surveys to obtain data about physicians’ services rendered to ambulatory patients during 
office visits. The questions asked were not sensitive, and therefore there were no 
expectations that the responses were laced with falsehood. Information collected from the 
surveys included service delivery, prescribed medication, patient characteristics, 
physician characteristics, and diagnoses.  
Scope and Delimitations 
The study may influence the approach taken in screening cancer patients for a 
comorbid diagnosis of depression. Comorbid depression can lead to a poorer cancer 
outcome, especially when the depression is not identified and treated (Zhu et al., 2017). 
Prompt identification and subsequent treatment lead to an improved patient experience 
(PDQ Supportive and Palliative Care Editorial Board, 2019). The study’s scope included 
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physician-patient encounters or visits focusing on patients with a cancer diagnosis 
irrespective of the cancer site who were screened for depression in the ambulatory care 
setting in the United States. The sampling design used to collect data was multistage 
probability sampling, which involved taking samples in stages using smaller and smaller 
sampling at each stage. 
The study was limited to physician-patient interactions occurring in the 
ambulatory care setting. As such, only variables related to physician-patient interactions 
were explored as independent variables. The results from this study create a foundation 
for exploring other predictors of depression screening among cancer patients. 
Limitations 
The potential limitations of this study should be noted. First, the data used in the 
analysis were cross-sectional, which did not allow for inferences regarding causation. 
Additionally, a potential limitation that may be related to using existing data from a large 
national database is study-specific nuances or glitches occurring during the data 
collection process, which may be important to the interpretation of some specific 
variables but may not be immediately obvious (Cheng & Phillips, 2014). Other 
limitations included those related to the collected variables, including lack of information 
on specific cancer types/sites. 
Significance 
Research is increasingly being evaluated by its significance and essential 
contributions to society and not just on its scientific impact (Bornmann, 2012). A 
dissertation topic focusing on establishing the factors associated with screening for 
15 
 
depression among patients with a cancer diagnosis can have a long-lasting positive effect 
on the population. As noted in the preceding section, cancer complicated by depression 
has important outcomes related to poor quality of life, increased cost of treatment, and 
higher morbidity and mortality. Therefore, this study determined the factors that predict 
which cancer patients will get a depression screening in the ambulatory setting. The study 
may contribute to society by stimulating new approaches to managing patients with 
comorbid conditions and informing public debates and policy-making strategies 
necessary to promote social change. 
Summary 
Depression occurring comorbidly with cancer continues to represent a significant 
public health problem. The burden on affected patients and their caregivers cannot be 
overemphasized. Improved depression diagnostic efforts followed by prompt treatment 
will go a long way toward alleviating the excess burden arising from the comorbidity. 
Gaining a deep understanding of how patients get screened for depression and the 
predictors for such screening should be one of the first steps in improving outcomes in 
patients with comorbid cancer and depression.  
In this chapter, I presented an introduction and background for the study's topic, 
including a summary of the literature. I emphasized the study’s public health significance 
and the problem associated with cancer and depression comorbidity and lack of adequate 
screening for depression among the patient population. I summarized the methodology 
that I used, including the study population and collection of secondary data. Additionally, 
I highlighted how the theoretical framework relates to each of the variables used in 
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defining the research questions. Finally, I discussed the study scope, delimitations, 
limitations, and anticipated assumptions.  
Chapter 2 will contain an extensive review of the literature covering the 
prevalence of depression and cancer, the interaction between depression and cancer, 
predictors of depression in cancer patients, determinants of depression screening among 
cancer patients, and access to depression screening. Importantly, the literature search 
strategy will be outlined. A historical account of the theoretical framework used will be 
discussed. Additionally, I will describe how the theory relates to the study, and how it 
will be appropriately integrated for application and use in the study. In Chapter 3, I will 
discuss the research methodology, which will be followed by the presentation of the 
study results in Chapter 4. I will conclude with Chapter 5, which will include a 




Chapter 2: Literature Review 
Introduction 
Depression occurs commonly among cancer patients, with some studies showing 
a pooled mean prevalence ranging from 8-24% (Krebber et al., 2014). Despite the high 
prevalence of depression among cancer patients, it is often unrecognized and untreated, 
thereby representing an enormous psychological distress source among the cancer patient 
population (Abid et al., 2018). Comorbid depression is associated with poorer cancer 
outcomes (Alemayehu et al., 2018; Smith, 2015). For example, the presence of comorbid 
depression significantly worsens the quality of life of cancer patients (Larkin, 2020). 
Compared with nondepressed cancer patients, depressed patients are more likely to have 
cancer that progresses and is invasive (Lin et al., 2018; Smith, 2015). Poor compliance 
with medical therapy and poor cancer survivability have also been identified as common 
outcomes of the co-occurrence of depression and cancer (Pasquini, & Biondi, 2007).  
While routine screening for depression has been recommended and endorsed both 
locally and internationally as an effective measure, the uptake of routine screening for 
depression among patients with cancer and other chronic disease conditions is not 
optimal (PDQ Supportive and Palliative Care Editorial Board, 2019). Existing published 
research has addressed the predictors, patterns, and trends of depression screening among 
adult populations with and without depression in the ambulatory care setting 
(Bhattacharjee et al., 2018; Harrison et al., 2010). However, there are currently no 
published studies investigating depression screening among cancer patients, including 
potential determinants and predictors of screening among this population in the 
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ambulatory care environment.  
The ambulatory care setting represents one of the most frequent contact points 
where patients with comorbidities meet with healthcare professionals (Carrera-Lasfuentes 
et al., 2015). Combined data analysis of the 2001 and 2002 NAMCS and National 
Hospital Ambulatory Medical Care Surveys (NHAMCS) found an average estimate of 
1.1 billion visits per year to physician offices, hospital outpatient departments, and 
emergency departments. This is an equivalent of 3.8 visits per person annually (Schappert 
& Burt, 2006). Despite the large volume of patient flow in ambulatory care settings, there 
is evidence of relatively good care coordination for patients visiting different specialists 
(Valderas et al., 2009). Comorbidity is related to the rate of utilization of ambulatory 
medical care (van den Bussche et al., 2011). This study determined the predictors of 
depression screening among cancer patients attending ambulatory care settings in the 
United States. 
The chapter will extensively review the literature relevant to screening for 
depression among patients diagnosed with cancer and the various predictors of 
depression screening in the patient population. The chapter will start with an outline of 
the HBM, the theoretical framework for this study. Specifically, I will review the 
prevalence of depression and cancer, the interaction between depression and cancer, 
predictors of depression in cancer patients, potential determinants of depression screening 
among cancer patients and/or patients with other chronic diseases, barriers, access to 
depression screening, screening, the prevalence of depression screening, and depression 
screening recommendations and patient outcomes. 
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Literature Search Strategy 
The databases searched included Medline/PubMed, Ovid, Embase, CINAHL, and 
PsycINFO. I also explored the Walden University Library and Google/Google Scholar 
search engines. In searching these electronic databases, I used specific search terms, 
including depression screening (screening and depression) AND cancer patients. The 
same combination of search terms was entered into all the databases. Reference lists of 
included articles were equally examined to identify further journal articles that might 
have been missed. Limits were placed in some of the databases to concentrate on relevant 
articles. Such limits included the English language, human, and articles published within 
the past 5 years. The article abstracts were exported to an Excel spreadsheet, and the 
articles were subsequently scanned to enable the removal of articles that appeared 
obviously out of scope. Articles that were the most pertinent were reviewed. While the 
searches were generally limited to 5 years (2015–2020), some research articles used to 
review the theoretical framework were older than 5 years. Some of these articles 
consisted of seminal articles to give the necessary historical account of the chosen theory 
as well as to establish the contextual facts and how the theory had evolved over the years.   
Theoretical Framework 
The HBM is one of the most extensively used health behavior theories (Glanz & 
Bishop, 2010). The model was originally formulated in the United States in the 1950s by 
social scientists working to explore the reason why people refuse to adopt preventive 
health behavior, including screening that can detect disease in the early phase 
(Rosenstock, 1974). The central tenet of the HBM was significantly influenced by the 
20 
 
theories of Kurt Lewin. The early social psychologists working on the theory of the HBM 
built most of their work on his theory.  
The HBM was originally conceptualized to include constructs relating to 
perceived susceptibility, perceived severity, as well as perceived benefits and perceived 
barriers (Rosenstock, 1974). Perceived susceptibility and perceived severity are 
indicative of a disease state, while perceived benefits and perceived barriers refer to the 
behavioral action that must be adopted by the individual to avoid or reduce the risk of a 
disease condition.  
Rosenstock (1974) described three different ways that individuals may internalize 
the construct of perceived susceptibility. Some individuals may not believe that they are 
susceptible to a disease. Other individuals may recognize the scientific possibility of a 
disease occurring but believe that they are unlikely to be affected by it. Finally, some 
individuals may acknowledge the presence of the real possibility of becoming affected by 
the disease.  
Perceived severity refers to the degree to which individuals believe that they can 
be negatively affected by a disease (Orji et al., 2012). Perceived benefits refer to adopting 
a health behavior based on the perceived advantages that an individual believes that the 
new behavior could lead to, in terms of subjective reduction of susceptibility to or 
severity of disease (Jones et al., 2015). Perceived barriers indicate the various negative 
actions or attributes associated with making a health behavior change (Jones et al., 2015). 
Perceived barriers could be unpleasantness and inconvenience associated with the steps 
necessary for the behavioral change, or barriers related to the financial cost of the desired 
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behavior change. All of these components work in concert to influence whether an 
individual acts or not.  
Approximately 20 years after the initial construct of the HBM was introduced, as 
more prospective studies were designed, the construct of self-efficacy was added to the 
HBM (Boslaugh, 2013). Self-efficacy is a concept that was originally developed by 
Albert Bandura, a social psychologist (Bandura, 1977). The concept refers to the 
confidence that people have about their ability to perform a behavior. An additional 
variable called cues to action was introduced, which was considered to be necessary to 
complete the model at the time. As individuals begin to consider making appropriate 
behavioral changes, the combination of susceptibility and severity in concert with the 
perception of benefits or fewer barriers may not be enough to stimulate the action 
required. A trigger, or a cue, appears to be necessary to complete the behavioral change 
cycle. Based on Rosenstock’s original description, cues to action could be internal cues 
by which an individual could perceive a change in bodily state or external cues such as 
interpersonal interactions. Cues to action could represent any factors that can instigate 
health behavior change or prompt an individual to take a health-related action. Over time, 
other modifying variables, such as social, psychological, and demographic factors that 
play important roles in individuals’ decisions to take action, were added to the HBM.  
Jones et al. (2015) described three basic models related to variable ordering that 
could be relevant to the operationalization of the HBM. In the first model (parallel 
mediation), the independent variables (e.g., gender and age) influence the HBM 
constructs, which in turn influence the dependent variable (e.g., screening for 
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depression). The model conceptualizes the HBM constructs as channels of influence, 
where the independent variables are seen as influencing outcome variables through one or 
more of the channels. The authors also described a second model in which each construct 
of the HBM connects in a causal chain. In the third model (moderated mediation model), 
individual constructs that form the HBM may serve as moderators for the other constructs 
to exert their influence toward stimulating a behavior change. For example, in order for a 
potentially predicted behavior to occur in the light of perceived benefits and perceived 
barriers, the perception of threat needs to be greater. In this example, the perception of 
threat moderates the effect or influence of both perceived benefits and perceived barriers 
on the specific behavior change (Champion & Skinner, 2008). 
The present study determined whether there is an association between screening 
for depression, the dependent variable, and the independent variables of age, gender, 
race, physician specialty, consultation with a mental health provider, and time spent with 
physicians among adults with a cancer diagnosis. Based on the HBM, a cancer patient 
who consults with a mental health provider contributes to risk perception (perceived 
susceptibility) for developing depression (Choudhry et al., 2016). Additionally, spending 
more time with physicians helps one to understand the depth of the risk (perceived 
severity) of the various physical, psychological, social, and economic complications of 
depression (Bhattacharjee et al., 2018; Wen et al., 2019). The tendency to discuss other 
related health issues outside of the primary cancer diagnosis is likely to occur as a 
function of how much time a patient and doctor spend together in consultation. 
Sociodemographic factors such as gender and age can influence the belief that depression 
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screening is useful and applicable (perceived benefits) for individuals diagnosed with 
cancer (Bhattacharjee et al., 2018; Wen et al., 2019). There is evidence that race may 
prevent individuals (perceived barriers) from ultimately taking preventive action, 
including undergoing depression screening (Hansotte et al., 2017; Wen et al., 2019). The 
specialty of the physician is an external trigger (cues to action) that activates discussion 
between patients and their physicians, and the possibility of getting screened for 
depression (Bhattacharjee et al., 2018; Wen et al., 2019). 
Specialists, including oncologists, pediatricians, and psychiatrists, are the health 
care providers with the most frequent contact with patients with potential comorbid 
depression and cancer in the ambulatory care setting and can potentially play vital roles 
in the detection of depression among the cancer patient population (Agapidaki et al., 
2013). Despite the pivotal position that these health care professionals occupy, the 
underrecognition and undertreatment of depression cannot be overemphasized. The 
literature has identified some specific health-care-provider-related barriers to screening 
for depression. These include attitudinal predisposition (Heneghan et al., 2007), 
inadequate dedicated time resources, increased workload, and poor communication 
between cross-functional team members (Horwitz et al., 2007). Few authors have used 
the HBM to explore the interaction of factors among health care providers that may 
predict or serve as barriers for depression screening among their patients. Agapidaki et al. 
(2013) examined the impact of an HBM-based educational intervention on pediatricians 
for the purpose of improving early identification and management of depression among 
mothers. The authors assessed the pediatricians’ knowledge, self-efficacy, and attitudes 
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concerning maternal depression at baseline and postintervention. They reported that 
pediatricians in the intervention group demonstrated increased perceived responsibility 
and increased self-efficacy for detection and referral of maternal depression.  
While there is a dearth of literature on the application of HBM constructs to 
determinants of depression screening among cancer patients, several authors have 
explored the role of HBM as a theoretical framework to study the predictors of screening 
for various health conditions. For example, VanDyke et al. (2017) applied the HBM as a 
determinant of breast cancer screening among 170 women aged 18-78 years in rural 
Appalachia. The frequency of mammography among respondents was found to be a 
function of an objective heightened risk and poorer prognosis of breast cancer, which is 
consistent with HBM expectations. Participants with poor prognosis also perceived 
greater benefits and fewer barriers to mammography screening. The authors, however, 
noted that mammogram frequency was not predicted by perceived susceptibility, severity, 
as well as benefits of mammography, a finding that did not completely fit into the HBM. 
Similarly, other authors demonstrated that women with lower perceived barriers to 
screening were more likely to undergo mammography compared to those with higher 
perceived barriers (Lee et al., 2015). In a prospective study that aimed to identify the 
predictors of intention to get screened and subsequent attendance at flexible 
sigmoidoscopy screening using constructs derived from the HBM, a higher score on a 
scale of benefits was positively associated with intention for screening, while intention 
was negatively associated with a higher score on perceived barriers. Attendance, 
however, was predicted by perceived benefits as well as perceived barriers (von Wagner 
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et al., 2019). 
Elias et al. (2017) explored the patterns and determinants of mammography 
screening among 2,400 Lebanese women ≥ 40 years of age. The association between 
having ever used and/or repeated mammography and psychosocial and sociodemographic 
factors was tested. Being older and of higher socioeconomic status (SES) were 
significantly associated with everuse of mammography. Compared to respondents that 
were designated “nonrepeaters,” “repeaters” were also significantly older. Specific to 
repetition of mammography, the psychosocial HBM variables that aligned best with the 
outcome of repeating mammography included higher perceived susceptibility to the 
disease, ease of access, and higher perceived comfort of the previous mammography 
encounter.  
Literature Review 
Prevalence of Depression and Cancer 
Depression represents the most common mental health disorder in the general 
population (Sinyor et al., 2016). According to a recent World Health Organization 
(WHO) report, approximately 4.4% of the world’s population, representing over 300 
million people at a global level, are estimated to suffer from depression (WHO, 2017). 
This represents an increase of 18.4% between 2005 and 2015 (GBD, 2015). The 
prevalence of depression in the population is difficult to estimate, partly because different 
researchers use different diagnostic criteria to measure depression. Some structured 
interview schedules that investigators have used to make an accurate and valid diagnosis 
and that have helped with prevalence measurement include the Diagnostic Interview 
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Schedule (DIS), the Schedule for Clinical Assessment in Neuropsychiatry (SCAN), and 
the Composite International Diagnostic Interview (CIDI; Brugha et al., 2001). A recent 
meta-analysis reported the aggregate point, 1-year, and lifetime prevalence of depression 
as 12.9%, 7.2%, and 10.8%, respectively (Lim et al., 2018). There is evidence that rates 
of depression are approximately twice as high in females compared to males (Baxter et 
al., 2014; Whiteford et al., 2013). The gender difference was present as early as age 12, 
peaked during the adolescent years, and first declined but then remained stable in later 
years (Salk et al., 2017). Depression is the leading cause of disability worldwide and one 
of the significant contributors to the global burden of disease (Friedrich, 2017). In the 
United States, depression is a significant cause of decreased workplace productivity, and 
up to $36.6 billion is lost every year as a result of poor workplace productivity caused by 
depression (Lépine & Briley, 2011). 
Cancer is a chronic disease that constitutes a major public health challenge around 
the world. In the United States, approximately 40% of men and women will have a 
diagnosis of cancer at some point in their lifetime (Arem & Loftfield, 2017). The 
commonest cancers among men include prostate, lung, colon, urinary bladder, and 
melanoma of the skin, while among females, the commonest cancers include breast, lung, 
colon, corpus and uterus, and thyroid (Cronin et al., 2018). From 2010 to 2014, the 
incidence rates of the seven commonest  cancers among men and women were reduced 
(Cronin et al., 2018). Although there was a 29% decline in overall cancer deaths between 
1991 and 2017, cancer continues to be one of the leading causes of mortality in the 
United States (Siegel et al., 2020). In 2020, 606,520 cancer deaths were projected in the 
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United States (Siegel et al., 2020). Based on data collected from 2001 through 2016/2017 
from the Centers for Disease Control and Prevention (CDC), National Cancer Institute 
(NCI)-funded population-based cancer registries, and the NCHS National Vital Statistics 
System, cancer death rates decreased on average by 1.5% per year from 2013 to 2017, 
1.8% per year among males and 1.4% per year among females (Henley et al., 2020). The 
burden of cancer continues to increase in the United States and worldwide (Arem et al., 
2017). Spending associated with cancer care is high and continues to grow, putting a 
huge strain on not only the nation, states, and health insurance plans, but also individual 
family budgets (Yabroff et al., 2019). 
There is an abundance of evidence from epidemiological studies that depression 
commonly occurs comorbidly with cancer (Nikbakhsh et al., 2014). Depression is a 
chronic disabling disorder that occurs in about 10-25% of cancer patients (PDQ 
Supportive and Palliative Care Editorial Board, 2019). Studies have demonstrated a 25% 
mortality rate for cancer patients with comorbid depressive symptoms, and a 39% 
mortality rate among cancer patients with full-blown major depressive disorders (Mustafa 
et al., 2013). The gender difference in depression incidence rate among the general 
population is reversed among cancer patients, as men with cancer report more depression 
symptoms than women with cancer (Pudrovska, 2010). This is in contrast to the general 
population, where the incidence of depression in women is almost twice the incidence in 
men (Baxter et al., 2014). There is evidence that cancer has more adverse psychological 
effects on men compared to women. Also, male cancer patients reported 1.4 more days 
per week of symptoms of depression compared to their matched controls without cancer 
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(Pudrovska, 2010). Cancer affecting the genitourinary system appears to have especially 
more adverse depressive symptoms among men.  
Interaction Between Depression and Cancer 
Comorbidity can be described as the co-occurrence of two disorders. As a 
generalization, a mental illness such as depression can occur with a medical condition 
such as cancer for three main reasons (Michael, 2007): 
1. The two conditions may occur together as a coincidence. 
2. The mental disorder or symptoms may have given rise to the medical 
condition; for example, anorexia nervosa may give rise to serious endocrine 
consequences that may lead to amenorrhea or severe bone loss. 
3. The medical condition, on the other hand, may have given rise to the mental 
disorder through either the effect of the medical condition and/or its treatment, 
adverse psychological response to the medical condition and/or its treatment, 
and/or adverse social response to the medical condition or its treatment. 
Depression is a mental illness that often occurs comorbidly with medical 
conditions such as cancer. In cancer patients, the etiology of depression could be 
multifactorial, and like the association between other mental illnesses and medical 
conditions, it could occur coincidentally. However, the association could also be 
psychosocial or biological (Smith, 2015).  
Some patients have depressive symptoms or a diagnosis of depression that predate 
their cancer diagnosis, while other patients develop depression after being diagnosed with 
cancer (Michael, 2007). Depression occurs as a result of chemical imbalances in the 
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brain. It also involves a complex pathology that transcends the neurobiological 
mechanism to include environmental stressors and genetic vulnerability.  
Often, the development of depression among cancer patients could be a 
psychological reaction to a cancer diagnosis. The symptoms of depression sometimes 
overlap with psychological reactions to the unpleasant news of a cancer diagnosis as well 
as some symptoms of cancer, such as poor sleep, pain, and tiredness (Michael, 2007). A 
cancer diagnosis represents a life-changing experience that a patient needs to negotiate 
and adapt to. A defective coping style may lead to poor adjustment, which may culminate 
in depressive symptoms or full-blown major depressive disorders (Chou et al., 2011). 
Indeed, psychological distress such as depression is well documented among patients 
diagnosed with life-threatening illnesses such as cancer (Jacobsen & Jim, 2008). The 
negotiation and the acceptance of a new diagnosis of cancer can be likened to the five 
stages of dying that were first described by Elisabeth Kubler-Ross, a Swiss psychologist 
in 1969 (Kübler-Ross, 1969). The stages are a psychological reaction to a severe life 
event. In the first stage, the patient is typically in denial, and it is not uncommon for 
him/her to believe there has been a mistake in the diagnosis or the prognosis. This may 
lead to the second stage, comprised of anger and frustration, especially when the 
individual realizes that denial cannot continue. The anger stage gives way to the third 
stage, i.e., bargaining. At the bargaining stage, the patient tries to negotiate to avoid a 
negative outcome. Commonly, patients may make remarks such as promising never to 
smoke again if their cancer can be cured (Tyrrell et., 2020). Depression is the fourth 
stage, and patients express despair and hopelessness. Patients then move on to the last 
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stage, which is acceptance. People respond to stress in different ways, including the use 
of coping strategies. The purpose of a coping strategy is to attenuate the effect of stressful 
events. Still, when the stress saturates the coping strategy or coping style of an individual, 
the ability to adjust may be impacted, leading to depressive symptoms.  
The social effect of having cancer and cancer treatment may facilitate the 
development of depression. For example, the loss of a job as a result of cancer may act 
synergistically with the patient’s underlying premorbid vulnerabilities, which can 
precipitate a depressive episode. Evidence of the interaction between social impact and 
depression in cancer patients was demonstrated by authors who showed that emotional 
support from family members and friends acts as a protective factor against the 
development of depression (Linden et al., 2012). Social support impacts both cancer and 
depression outcomes in  patients with comorbid cancer and depression. Some authors 
have shown that cancer survivability improved significantly among patients with 
adequate social support, and in addition to the survival benefits , the level of depression 
and other mental disorders were significantly reduced (Kroenke et al., 2006; Hopko et al., 
2015). Additionally, cancer treatment can act as a stressor which in vulnerable patients, 
and within the right environmental milieu, could lead to depression (Michael, 2007). In 
terms of biological interaction, some authors have identified uncontrolled pain, metabolic 
and endocrine abnormalities, as well as concomitant medications as potential medical 
causes of depressive symptoms in people with cancer (PDQ Supportive and Palliative 
Care Editorial Board, 2019).    
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Predictors of Depression in Cancer Patients 
Over the past decades, there have been significant advances in cancer treatment. 
As a result, the number of patients surviving a diagnosis of cancer continues to grow. In 
the approximately 1.6 million people diagnosed with cancer every year, the relative 5-
year survival rate across all cancer types approaches 70-78% (Allemani et al., 2018). As 
more patients continue to transition into cancer survivorship, it is critical to understand 
both the short-term and long-term psychosocial adjustment that is part of the disease 
process. Depression is particularly common among this patient population; hence it is 
crucial to study the markers, predictors, and trends in depression screening among cancer 
patients. 
Several potential predictors of psychological distress and depression among 
cancer patients have been identified, including the need to relocate for treatment and 
being a former smoker (Clinton-McHarg et al., 2014), tumor stage (Tsuguo et al., 2013), 
psychosocial factors (Godding et al., 1995; Hamilton et al., 2013), and quality of life 
(Godding et al., 1995). A few researchers have explored the different factors that 
influence how cancer patients adjust to their cancer diagnosis and how these are 
associated with the development of psychological symptoms such as depression. 
Schapmire and Faul (2017) investigated predictors of depressive symptoms over a period 
of eight years among respondents ages 50 – 91 years. They found that a diagnosis of 
cancer in patients without aspouse/partner in the home, and cancer diagnosis and lower 
life expectancy were associated with a higher probability of having a concurrent 
depression. The authors also identified a significant three-way interaction between 
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cancer, gender, and social support, in which female cancer patients with poor social 
support were found to be at a higher risk of developing depression. Other studies did not 
find a significant relationship between social support and depression among cancer 
patients. Yoon et al. (2018) examined the relationship between social, cultural, and 
appraisal factors and depression and quality of life among Korean American population. 
While the authors demonstrated a statistically significant relationship between higher 
levels of social support and higher quality of life, they failed to establish a statistically 
significant relationship between social support and depression. However, they still found 
that more negative appraisal of illness tended to predict the development of depression 
among cancer patients (Yoon et al., 2018). However, other authors that have studied a 
similar population of Korean Americans reported that social support was significantly 
related to depression in cancer patients (Hae-Ra et al., 2008). The two studies used 
different social support measures, and the sample characteristics were also different, 
which may have explained the differences in the two studies. More evidence of social 
support as a predictor of depression among cancer patients has been reported in other 
recent literature. Specifically, the absence of a partner was identified as a risk factor for 
developing depression among patients with gynecological malignancies (Klügel et al., 
2017).  
Other authors have suggested that the degree of social support a cancer patient 
receives may not be as important as the ability of cancer patients to receive compassion 
from others as a predictor of depression symptomatology. For example, Trindade et al. 
(2018) explored the predictors of depressive symptoms in a sample of patients diagnosed 
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with breast cancer. Social support and fear of receiving compassion from others were two 
predictors examined. The authors found that the fear of receiving compassion from others 
was a significant predictor but not social support.   
There is increasing evidence of the relationship between depression and sexual 
function among cancer patients. For example, in a study of 83 women that were 
successfully treated for their stage 1b cervical cancer, psychological distress scores were 
significantly correlated with sexual outcomes, functional outcomes and physical 
complaints (Cull et al., 1993). The authors reported that the 61 women who admitted to 
optimal sexual experience prior to treatment all reported a sexual function that was 
significantly poorer compared to pre-morbid sexual function. Similar trends have been 
consistently reported in the literature among similar populations (Lau et al., 2013). More 
recently Klügel et al (2017), conducted a critical review of the literature and identified 
sexual inactivity as one of the factors that predicts depression among patients diagnosed 
with cancer.   
Age has been shown to be one of the sociodemographic factors that is 
significantly associated with depression among cancer patients. Wondimagegnehu et al 
(2019) demonstrated an inverse association between depression andage. Specifically, the 
authors showed that the risk of having depression decreased by as much as 60-80% as 
age increased. Patients that were greater than 30 years of age tended to have a lower risk 
of depression than those 19-20 years of age. Similarly, a study that examined the 
demographic factors associated with continuous distress in the year following cancer 
diagnosis reported younger age as a predictor of occasional or continuous distress, 
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including depressive symptoms in cancer patients (Enns et al., 2013). Vodermaier et al. 
(2011) also reported that fewer depressive symptoms were observed in older cancer 
patients. 
Determinants of Depression Screening Among Cancer Patients 
The purpose of screening for depression among cancer patients seeking treatment 
is to promptly identify patients with otherwise unrecognized symptoms of depression 
seeking cancer treatment for subsequent referral to confirm a minor or major depressive 
disorder and for subsequent treatment (Meijer, et al., 2011). There is a dearth of 
information on the potential predictors of screening for depression in cancer patients. In 
addition, few studies have investigated predictors of depression screening among non-
cancer study populations. Two studies used pooled data from the National Ambulatory 
Medial Care Survey (NAMCS), a nationally representative sample. In one of these 
studies, Bhattacharjee, et al. (2018) examined the predictors of and trends in depression 
screening among adults without a diagnosis of  depression who made an ambulatory care 
visit to a non-psychiatrist. The authors found that the amount of time spent with the 
physician, geographical region and metropolitan location, physician specialty, as well as 
gender of the patient were significantly associated with receipt of depression screening.  
Barriers and Access to Depression Screening 
The importance of prompt access to screening for mental health and the ability to 
identify patients in need of both initial and follow-up care cannot be overemphasized. 
However, there have been extensive studies demonstrating significant disparities in the 
recognition and treatment of depression. Some of these studies have established that 
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racial-ethnic inequalities constitute a major problem, with people of minority groups 
having the least probability of screening for depression (Roberto et al.,2005). A study that 
evaluated disparities in depression screening and care by gender and race of patients 
found wide variability by gender, implying the need to consider interactions among 
patient variables as opposed to exploring screening and mental health utilization based on 
consideration of a single segment of the population (Hahm et al., 2015).  
Barriers to screening for depression are multifactorial and could be classified into 
those factors relating to the patients and those relating to health care providers. Patient-
related factors include the inability to find childcare, problems accessing transportation, 
and other challenges specific to role responsibilities of women. These factors represent 
specific barriers to accessing depression care, such as depression screening (Hahm et al., 
2015). Patients generally perceive that their providers are prone to neglect their 
psychosocial needs compared to their physical needs (Adler & Page, 2008). This 
disparity may be due to a lack of providers of the same racial-ethnic background whom 
they can trust and not feel stigmatized. Differences in language, barriers related to health 
literacy, predominant somatic presentation, and use of cultural idioms of distress during 
presentation to health care providers make under-recognition of depression a notable 
problem, particularly among minority ethnic groups (Roberto et al., 2005). Making a 
diagnosis of depression requires skills and a thorough assessment of patients.  Greenberg 
(2004) reported that there is enormous lack of confidence and self-efficacy among 
clinicians that are not psychiatrist in confidently making a diagnosis of depression among 
cancer patients, which is usually compounded by the time demand on the health care 
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provider. Indeed, lack of time has been shown to be the main barrier to the successful 
screening for distress and other mood-related symptoms, such as depression, among 
cancer patients (Mitchell et al., 2008). The study also found other factors related to the 
health care provider, such as sub-optimal training and low confidence, which constitute 
essential barriers to screening.    
Healthcare providers may tend to focus more on physical symptoms co-occurring 
with cancer than depression and other psychological symptoms. Alison et al. (2016) 
explored whether there was any difference between screening for physical versus 
emotional symptoms by the providers of cancer patients. While they found no significant 
variation, they reported a lower tendency to screen for emotional symptoms, including 
depression, compared to pain and other types of physical symptoms.    
Screening 
The conference on Preventive Aspects of Chronic Disease held by the 
Commission on Chronic Illness in 1951 defined screening as “the presumptive 
identification of unrecognized disease or defect by the application of tests, examinations, 
or other procedures which can be applied rapidly. Screening tests sort out apparently well 
persons who probably have a disease from those who probably do not. A screening test is 
not intended to be diagnostic. Persons with positive or suspicious findings must be 
referred to their physicians for diagnosis and necessary treatment” (Commission on 
Chronic Illness, 1957 Chapter 5, p. 45). The World Health Organization report (WHO) in 
1966 further elaborated on the definition of screening and the principle of early detection 
of disease and scientific aspects of screening procedures. From the initial definition, the 
37 
 
WHO noted that “other procedures” could also potentially embrace the use of 
questionnaires in screening (World Health Organization, Wilson, & Jungner, 1966). The 
U.K. National Screening Committee in 2000 further defined screening as “a public health 
service in which members of a defined population, who do not necessarily perceive they 
are at risk of or are already affected by, disease or its complications, are asked a question 
or offered a test to identify those individuals who are more likely to be helped than 
harmed by further tests or treatment to reduce the risk of disease or its complications” 
(page 6). The definition of and emphasis on the science of screening have evolved over 
the years with more focus assigned to the potential side effects arising from the screening 
procedures and potentially no benefit to the patient being screened. Emphasis has been 
placed on the need for more rigorous standards of evidence to improve the effectiveness 
of all screening. Reduction in morbidity and mortality due to the early detection of 
disease drives the objective of screening tests, especially when a treatment exists for the 
condition being tested for (Maxim et al., 2014). As part of the appraisal, viability, 
effectiveness, and appropriateness of a screening program, the National Screening 
Committee (U.K.) proposed a set of criteria that must be met before screening for a 
condition is initiated (Kitchener, et al., 2014). These include an emphasis on the 
condition being screened for (which should be an important health problem), the test 
(which should be simple, safe, precise, and a validated screening test), the treatment 
(implying that there should be an effective treatment for all patients identified through 
early detection with better outcomes compared to late treatment) and finally, the 




Prevalence of Depression Screening 
Despite the numerous local and international guidelines that have recommended 
routine screening for depression among medical patients, including cancer patients, 
depression remains highly unrecognized (Ng, How, & Ng, 2016). While there are not 
many studies on the prevalence of depression screening among cancer patients, there are 
few studies that have reported on the prevalence rates of depression screening among the 
adult population in general (Desai et al., 2006; Farr et al., 2011; Tudiver et al., 2010). 
Desai et al. (2006) conducted a chart review of the Department of Veterans Affairs (VA) 
medical outpatients with no history of depression or any mental health visit within the 
past six months. The authors found that while younger and unmarried patients and 
patients with more medical comorbidity were more likely to be positive when screened, 
they were generally less likely to be screened.However, VA facilities that tended to spend 
more on mental health care were more likely to screen for depression. A similar study 
that also conducted a chart review of women’s records in 19 rural health clinics reported 
that patients with a history of anxiety as well as younger women had higher probabilities 
of being screened (Tudiver et al., 2010). In terms of patients’ gender, some studies 
reported no difference in depression screening rates between women and men among 
patients of all ages (Desai et al., 2006). Harrison, et al. (2010) estimated the probability of 
screening for depression among U.S. adults using a nationally representative sample and 
reported a 2.29% prevalence of depression screeningduring community-based physician 
practice visits. Other authors reported a lower nationallevel depression screening 
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prevalence rate of 1.4% (Bhattacharjee et al., 2018). The two studies occurred at a time 
during which the USPSTF recommendation for depression screening among adults was 
dependent on the presence of programs that could assure follow up treatment of those that 
screened positive (Siu et al., 2009). The recommendation was subsequently revised to 
accommodate screening for all adults irrespective of available capacity to follow up with 
treatment (Siu et al., 2016). The low prevalence reported by these authors could have 
been a factor of the older recommendation by USPSTF (Bhattacharjee et al., 2018).  
There is evidence that residents and physicians working in specialties other than 
psychiatry are not adequately prepared to recognize depression. Dietrich and colleagues 
(2003) conducted a survey among obstetrics/gynecology residents in their final year or 
recent graduates concerning their attitude related to depression care. They found that less 
than 50% of the respondents acknowledged that they were well prepared to identify 
depression in their patients. Not more than 12% of the respondents routinely inquired 
about depressive symptoms, and the recognition of symptoms was predominately based 
on patients’ distressed appearance as well the patient talking about depression directly. 
The role of primary care physicians in depression screening has also been studied. 
Glasser et al. (2016) conducted a cross-sectional study of primary care physicians 
regarding their attitudes and practices in managing depression in the post-partum period. 
Family medicine physicians were found to be more willing than pediatricians to screen 
for depression. However, there was no difference between physicians by gender when 
comparing all respondents. 
Depression Screening Recommendation and Patient Outcome in Cancer 
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Cancer continues to be the leading cause of death in the U.S. with more than 
1,806,590 estimated new cases and 606,520 deaths expected in 2020 (Siegel et al., 2020). 
Considering the advancement in cancer diagnostics and treatment options, the overall 
outcome of cancer cases can still be described as poor, and cancer is still one of the most 
dreaded diseases. Comorbidity with depression contributes an additional burden to 
patients that are affected. For example, the quality of life of patients with comorbid 
cancer and depression is significantly lower compared to cancer patients without 
depression (Wondimagegnehu, et al., 2019). This reduced quality of life  has been 
partially attributed to the frequent lack of recognition of depression in cancer patients. As 
a generalization, there are indications that there is a high prevalence of undiagnosed 
depression in the general and cancer populations (Popoola & Adewuya, 2012; Lloyd-
Williams, 2003). Williams, et al. (2017) explored the prevalence of undiagnosed 
depression in a lower-income neighborhood in northern Manhattan, and reported that 
approximately 7.6% of depressed patients go unrecognized, leading to a  missed 
opportunity for screening, and this missed opportunity is associated with greater mortality 
and reduced quality of life.   Several guidelines support recommendations that patients 
diagnosed with cancer be routinely screened for the presence of psychological distress, 
including depression (Kitchener, et al., 2014). The National Comprehensive Cancer 
Network (NCCN) established a panel comprising an interdisciplinary group that 
published a guideline recommending that all cancer patients be routinely screened for 
distress and psychosocial needs. The panel came up with a broad definition of distress  as 
a “multifactorial, unpleasant experience of a psychological (i.e., cognitive, behavioral, 
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emotional), social, spiritual, and/or physical nature that may interfere with one’s ability to 
cope effectively with cancer, its physical symptoms, and its treatment” (NCCN, 1999). 
Distress was described along a continuum to include depression. Three years after the 
initial guideline from NCCN, the U.S. National Institutes of Health (NIH) convened a 
state-of-the-science conference and recommended that cancer patients be routinely 
screened for depression using brief screening tools (National Institutes of Health, 2003). 
In 2007, the Institute of Medicine (IOM) released a report that showed that the 
psychological needs of cancer patients were not adequately addressed and similar to other 
guidelines, recommended that cancer patients be screened for psychological distress 
(Institute of Medicine, 2007). Also, routine depression screening of all adults has been 
recommended by the U.S. Preventive Services Task Force (USPSTF) since 2009 (Siu et 
al., 2016). 
Studies have explored the linkage between screening for depression and 
appropriate treatment following the screening.  There is evidence that depression 
treatment in the general population is associated with a better outcome and good response 
to treatment (Duval et al., 2006). However, some studies have shown that not all 
screening culminates in follow-up care for depression. For example, a study showed that 
at six-month follow-up of depression screening in a community health fair, none of the 
participants that screened positive for depression and were given a referral made a 
follow-up appointment at the community mental health agency (Opperman et al., 2017). 
However, it is essential to note that the authors did not factor the fact that some 
participants could have followed up with other health care providers outside of the 
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referral agency. Indeed, the authors recommended integrating and evaluating the 
effectiveness of a brief on-site consultation by mental health professionals to assess any 
potential depressive f symptoms fully. 
Depression Screening in Cancer Patients 
The importance of screening tools in the assessment of depression among patients 
with cancer cannot be over emphasized. Depression continues to pose a significant 
psychological disruption among cancer patients, especially because it is often 
unrecognized and inadequately treated (Caruso et al., 2017). Approximately 50-60% of 
cancer patients with depression are unrecognized in clinical practice (Grassi et al., 2010). 
In response to the trends in depression recognition and treatment in cancer patients, 
several guidelines and screening instruments have been developed (Siu et al., 2016; 
Kitchener, et al., 2014). Examples of screening instruments that have been used in 
screening depression among cancer patients include: 
1. The nine-item Patient Health Questionnaire (PHQ-9) 
2. The Distress Thermometer (DT) 
3. The Hospital Anxiety and Depression Scale (HADS) 
4. The Psychological Distress Inventory 
5. The Brief Symptom Inventory 
6. The Edinburgh Depression Scale 
7. The Zung Self-Rating Depression Scale 
8. Single-item interview 
9. The Beck Depression Inventory (BDI) 
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10. The Hopkins Symptom Checklist (HSCL) 
11. Center for Epidemiologic Studies Depression Scale (CES-D) 
Wakefield et al (2015) conducted a meta-review of patient-reported depression 
measures used in screening depression in the oncology space. This included a review of 
more than 50 depression screening measures that are used in patients with any cancer 
type. The authors reported that while the HADS was the most widely studied screening 
instrument, the wide variability in its recommended cut-points represents an important 
limitation to its use.   The BDI was notably highlighted as a more generalizable screening 
instrument across cancer types and disease stages with greater potential for screening and 
case finding. Relative to responsiveness, the Center for Epidemiologic Studies 
Depression Scale (CES-D) was reported to be the best-weighted measure. 
Several authors have explored the ability of different screening procedures to  
detect mood disorders, including depression among cancer patients. For example, 
Wagner et al (2017) explored the feasibility, sensitivity, and specificity of commonly 
used screening instruments to detect depression among cancer patients receiving 
definitive or palliative radiotherapy in community-based radiation oncology settings. The 
authors found a good completion rate of the depression screening procedures, indicating 
that depression screening in the oncology settings is highly feasible. While comparing the 
ability of the PHQ-2, PHQ-9 and National Comprehensive Cancer Network-Distress 
Thermometer (NCCN-DT) to detect depression, they concluded that the PHQ-2 is an 
effective tool for identifying cancer patients with mood disorders, including depression, 
and is comparable to the longer PHQ-9 and superior to the widely used NCCN-DT. 
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Other authors have studied the accuracy of depression screening instruments 
among specific cancer patients. Katz et al (2004) examined the BDI, the HADS and the 
CES-D scale among ambulatory head and neck cancer patients who had received 
radiation and who were evaluated for major and minor depression using the Schedule for 
Affective Disorders and Schizophrenia (SADS). While all three depression instruments 
were reportedly accurate in terms of sensitivity, specificity and positive predictive value 
(PPV), the HADS demonstrated the highest level of accuracy and was found to be 
potentially most useful. Similarly, the diagnostic accuracy of four different depression 
screening instruments (CES-D, BDI-FastScreen, PHQ-9, and a 1-item screener- “Are you 
depressed?”) were compared to the gold standard structured Clinical Interview-DSM IV 
among ovarian cancer patients undergoing treatment (Shinn et al., 2017). The authors 
concluded that the PHQ-9 had the best diagnostic accuracy among the four screening 
instruments explored. The CES-D with the traditional cutpoint of 16 and the one-item 
screener were the worst methods.  
Some authors have explored the degree of agreement between HADS and clinical 
assessment outcomes as a function of age, sex, and treatment intention.   Thalén-
Lindström et al., (2016) reported a moderate agreement between HADS and clinical 
assessment for identifying depression among 146 oncology patients with either curative 
or palliative treatment intention. However, the greatest difference between HADS and 
clinical assessment was found to be on the basis of age and sex. While agreement was 
determined to be better for females compared to males for distress and anxiety, 
agreement was better for participants age ≥65 year compared to participants age <65 year 
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in relation to depression. Agreement between HADS and clinical assessment was 
moderate in relation to whether the treatment intention was curative or palliative.  
A variety of cut-off scores have been recommended for each of the depression 
screening instruments. The relatively wide variation has led to some degree of challenge 
over where to set the threshold for identifying depression cases among cancer patients. 
Vodermaier and Millman (2011) conducted a meta-analysis to identify empirically 
derived cut-offs for the HADS, which is the most widely validated scale for screening for 
emotional distress in cancer patients. The authors reported that the HADS total scale and 
HADS depression subscale demonstrated good accuracy for measuring depression, 
compared to mental disorders in general. On the HADS total, HADS depression subscale, 
and HADS anxiety subscale, they identified a threshold of 15, 7, and 10 or 11, 
respectively, as an appropriate cut-off for depression screening.   
Several other screening methods have been developed for use in identifying 
depression among cancer patients. Most of the assessment methods were developed to 
overcome specific challenges peculiar to traditional screening instruments. For example, 
the use of a smart phone application for screening for depression could potentially 
eradicate the barrier posed by regular screening in patients who rarely visit their 
physicians (Kim et al., 2016). Kim et al (2016) conducted the first study that examined 
the validity of a mobile app depression screening device among patients with breast 
cancer. The authors compared the performance of depression screening using a mobile 
mentalhealth tracker with the results from PHQ-9 tests and reported that the two 
screening methods where comparable. The expression of certain emotional states, 
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including depression, is known to be affected by cultural background, whereby some 
cultures do not encourage negative expression considered disruptive (Bae & Park, 2016). 
Therefore, the use of depression screening tools that can by-pass the need for patients to 
complete questionnaires about their symptoms could be valuable. Kim, et al (2018) 
evaluated the use of Diagnostic Drawing Series (DDS) as a screening tool to identify 
psychological distress among breast cancer patients, which could supplement the 
traditional depression screening questionnaires. The authors concluded that DDS could 
be used as a supplemental screening tool to identify psychological distress, including 
depression, among breast cancer patients. 
Summary 
Chapter two represents a synthesis of the information on the screening for 
depression among cancer patients in the ambulatory care setting in the U.S. The various 
predictors and determinants of depression screening were also reviewed. The prevalence 
of cancer and depression and their comorbidity was discussed. A thorough review of the 
potential pathophysiology, interaction, and explanation of why depression may co-occur 
with cancer was presented. Evidence suggests defective coping mechanisms, 
psychological reactions, mere coincidence, and social and biological mechanisms.   
A review of the barriers to and access to depression screening guided the 
opportunity to explore the potential determinants of depression screening in cancer 
patients. The review of the literature uncovered that there is a scarcity of information 
regarding the predictors of depression screening specifically among patients diagnosed 
with cancer. The extensive review of the historical path of screening and the local and 
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international guidelines provided context to the importance of screening and important 
criteria to be considered before making decisions on whether to screen for a particular 
disease.  
Finally, the different depression screening instruments that have been validated 
for use in cancer patients were explored. While there are several instruments that have 
been validated, the varying cut-offs represent a challenge in deployment among patients. 
The HADS is the most widely used, while the PHQ-9 appears to have the best diagnostic 
accuracy. 
Overall, there is limited to no information on the predictors of depression 
screening among cancer patients. The current review explored existing literature but is in 
no way exhaustive or conclusive about all the potential predictors. One of the major 
findings of the current literature review is the uncovering of a need for further research 
work in identifying the predictors of depression screening among cancer patients. The 
current research study sought to identify some of the potential predictors of depression 
screening using the HBM as the theoretical background. The study analyzed secondary 
data from the National Ambulatory Medical Care Surveys (NAMCS). Chapter three 
outlines and discusses both the quantitative and the methodological approach needed to 
scientifically summarize and analyze the data.  
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Chapter 3: Research Method 
Introduction 
The purpose of this study was to explore and establish the factors that predict 
depression screening among cancer patients in the ambulatory care setting in the United 
States. Suitable statistical analyses were conducted to determine whether each of the 
proposed predictors impacts the likelihood of cancer patients undergoing depression 
screening. Several guidelines have recommended depression screening among cancer 
patients. This study gives support for that recommendation and for all efforts geared 
toward the prompt identification of cancer patients who may require additional treatment 
for depression.  
This study’s findings may contribute to the development of tailored interventions 
targeted at factors in cancer patients that predispose them to not screening for depression. 
The correlation between depression and poor cancer survivability has underscored the 
need for timely screening for depression accompanied by adequate treatment (Sherrill et 
al., 2017). To further explore how depressed cancer patients can be identified more 
quickly and get connected to much-needed treatment, I sought in this study to determine 
the potential predictors of depression screening among cancer patients. Depression 
screening is an important first step toward identifying cancer patients at risk for 
depression; therefore, the importance of understanding the determinants of screening 
cannot be overemphasized. While there are authors who have explored predictors of 
depression screening among the adult population, there are currently no studies in the 
literature that have sought information on factors that predict which cancer patients will 
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get screened for depression. 
In this chapter, I describe the research design and rationale and discuss the study 
methodology, including the population and sampling procedures. Potential validity 
threats and ethical procedures are also addressed. The chapter concludes with a summary 
of all procedures highlighted. 
Research Design and Rationale 
This study used data from the NAMCS. The NAMCS is a publicly available 
national survey conducted by the NCHS of the CDC (NCHS, n.d.-a). The initiative is part 
of the National Health Care Survey’s effort to measure healthcare utilization across 
various healthcare providers. Specifically, the survey was created to generate objective, 
reliable data about the provision and utilization of ambulatory medical care services in 
the United States. In this study, I analyzed visits to nonfederally employed, office-based 
physicians directly involved in patient care. The category of office-based physicians 
excluded radiologists, anesthesiologists, and pathologists. Using the dataset, I specifically 
examined those physician visits that involved the exploration of depression screening 
among cancer patients. 
Research Design 
A cross-sectional design was used in this study. The data that I analyzed 
originated from the 2014-2016 NAMCS database. The NAMCS database contains 
information from an annual probability survey sent to participating nonfederal office-
based physicians within the 50 U.S. states and the District of Columbia. The physicians 
who took the survey were selected using an intricate sampling design, resulting in a 
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systematic random sample of office-based visits. The U.S. Bureau of the Census acts as 
the field data collection agent for the NAMCS.  
The data collection strategy was designed to minimize data collection workload 
and to maintain approximately equal reporting levels among sample physicians, 
irrespective of their practice size. The process was achieved through data collection 
(performed by the physician or physician’s staff) from 30 randomly selected patient visits 
during a randomly assigned, 1-week reporting period (NCHS, n.d.-b). Based on the cross-
sectional view afforded by the NAMCS dataset, it is scientifically justifiable to identify 
independent variables that could potentially predict the independent outcome of 
depression screening. 
Data Eligibility Criteria 
In 2016, the U.S. Preventive Services Task Force (USPSTF) updated its 
guidelines to include a recommendation for routine depression screening in patients age 
12-18 years (Siu et al., 2016). Rates of depression among adolescents and young adults 
with cancer are higher than those in older adults with cancer (Park & Rosenstein, 2015). 
Therefore, visits for adolescents were included in the study. Specifically, visits for 
patients who were ≥ 12 years of age, with or without depression and with a diagnosis of 
cancer, who made an ambulatory care visit to an office-based physician were included in 
the study.  
Visits were excluded if “yes” was not indicated for the question “Does patient 
now have cancer?” Visits to physicians in the anesthesiology, pathology, and radiology 
specialties, including designated subspecialties, were also excluded from the study. All 
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patient visits that were primarily related to conditions in which depression screening 
would be highly unlikely to occur, such as visits related to injuries and for administrative 
purposes, were also excluded. It is also important to note that only office-based visits to a 
physician were included in the dataset. Federally based physician office visits were not 
included in the dataset. 
Case Definition 
The identification of patients with cancer and depression, and thosewho had 
undergone depression screening during ambulatory care visits, was determined based on 
the provider’s affirmation in response to specific questions. Cancer ambulatory care visits 
were selected if the provider indicated an affirmative response to the question 
“Regardless of the diagnosis previously entered, does the patient now have cancer?” The 
event was recorded irrespective of the list of diagnoses related to the current visit.  
Cancer included any cancer type and was generally not limited to any specific 
body site. Similarly, depression was identified whenever the provider checked the box 
corresponding to the question “Regardless of the diagnosis previously entered, does the 
patient now have depression?” During a visit, the provider marked all services, including 
examination and screening, provided during that visit. In the NAMCS database, 
depression screening was dichotomized with a yes/no response. No specific depression 
screening type or procedure was identified. There was also a section on the NAMCS 
patient record designated as “providers.” The type of provider seen at the visit was 
indicated, with possible selections including physician, physician assistant, nurse 
practitioner/midwife, RN/LPN, mental health provider, other, and none. 
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Additionally, the patient’s age (in years, months, and days), sex, and race were 
collected. For this study, age, sex (defined as male or female), race (defined as White, 
Black or African American, Asian, Native Hawaiian or Other Pacific Islander, or 
American Indian or Alaska Native), and physician specialty represented the independent 
variables, while depression screening was the dependent variable. Geographic regions 
included Northeast, Midwest, South, and West. 
Methodology 
Population 
The number of new cancer cases worldwide has been projected to reach 
approximately 26 million, with 17 million cancer deaths per year by 2030 (Thun et al., 
2010). In the United States, close to 2 million new cases of cancer have been estimated to 
occur in 2020, with approximately 34% of those patients expected to die in 2020 (Siegel 
et al., 2020). The prevalence of depression among newly diagnosed patients and patients 
chronically affected by cancer is significant (Wagner et al., 2017; Walker et al., 2013). 
Depression screening has been recommended to identify cases promptly and connect 
patients with treatment (Siu et al., 2019).  
For this dissertation, the study population included patients visiting the 
ambulatory care setting in the United States with a cancer diagnosis. The NAMCS 
captures nationally representative healthcare services provided in ambulatory care 
settings in the United States. Surveys are administered cross-sectionally to record 
physician-patient encounters or visits. For the purpose of the survey, a visit was defined 
as “a direct, personal exchange between a physician, or a staff member operating under a 
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physician’s direction, for the purpose of seeking care and rendering health services” 
(NCHS, 2017a). The study sample included both male and female patients 12 years of 
age and above who reported a diagnosis of cancer at an ambulatory care visit. 
Sampling and Sampling Procedures 
Sampling Strategy 
Secondary data were drawn from 3 consecutive years of the NAMCS (i.e., from 
2014 to 2016). These data pertained to depression screening among patients with a 
current diagnosis of cancer. The survey response rates for physician-level responses for 
the core NAMCS samples covered in this study in 2014, 2015, and 2016 were 54.8%, 
46.0%, and 46.0% (weighted), respectively. The sampling design of the NAMCS consists 
of a cross-sectional, multistage probability survey of visits to office-based physicians. A 
stratified two-stage sample in which physicians were selected in the first stage and visits 
were selected in the second stage was used as the sampling design. The American 
Medical Association and American Osteopathic Association maintained the master files 
from which a stratified sample list of physicians was selected. 
Each of the sampling strata was defined by census region and physician specialty 
group. The census regions included Northeast, Midwest, South, and West. The 15 
physician specialties that were included were as follows: 
 general and family practice,  
 osteopathy, 
 internal medicine,  
 pediatrics,  
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 obstetrics and gynecology,  
 general surgery,  
 orthopedic surgery,  
 cardiovascular diseases,  
 dermatology,  
 urology,  
 psychiatry,  
 neurology,  
 ophthalmology, 
 otolaryngology, and 
 a residual category for all other specialties. 
Dataset Access 
This study used the NAMCS dataset. The NCHS offers the NAMCS data as freely 
downloadable, public-use data files through the CDC FTP file server. Permission is not 
required to download the data. The service is freely available to users, and appropriate 
datasets, documents, and questionnaires from NCHS surveys, including all data 
collection procedures, can be downloaded. Instructions for downloading files are 
provided on the website in “readme” files. The data are available in self-extracting, 
compressed data files. Data extraction is complete after downloading the data. All that is 
therefore needed to access the dataset is access to the internet. The dataset is available for 
download to be used with various statistical software, including SAS, STATA, and SPSS. 




An essential aspect of study design is sample size calculation. The sample size 
refers to the number of study participants who need to be enrolled in a research study to 
detect a clinically significant treatment effect. Simply put, sample size is the number of 
participants in a sample (Kadam & Bhalerao, 2010). While a study with an inadequate 
sample size may make it difficult to detect any meaningful effect, having too many 
respondents included in a sample may impact the results of a research study by producing 
a statistically significant yet clinically insignificant result (Hickey et al., 2018). This 
important methodological concept underscores the importance of appropriately 
calculating the sample size at the study design stage of a research project.   
To determine the sample size for this study, I utilized the computer software 
G*Power 3.1 (Faul et al., 2009). This software is available for free download and 
installation and has an intuitive interface that eliminates unnecessary complications 
related to sample size determination. There are two crucial points that users must note 
before conducting sample size calculation using this software: 
1. The researcher must determine the right statistical test to use. 
2. The researcher must understand what the predictor variables are. 
The software allows the user to choose a statistical test; for this study, I chose 
logistic regression. Logistic regression aligned with my research question, with a 
dichotomous dependent variable and both binary and continuous independent variables. 
The odds ratio option was selected for entering the expected effect size. The study tested 
whether different independent variables (e.g., sex as a dichotomous variable) were 
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significant predictors of a binary outcome variable. In the G*Power software, two tails 
were chosen, and for test family and statistical test, the z test and logistic regression were 
selected. The power calculation was based on the assumption that for gender, women and 
men with cancer will have a 50% and 30% probability of being screened for depression, 
respectively. The error probability was set at 0.05, and to be able to demonstrate an 
association between the independent and dependent variables, given that an association 
exists, the power was set at 0.95. Based on these parameters, the sample size was set at 











Instrumentation and Operationalization of Constructs 
NAMCS was launched in 1973 and developed as a product of more than six years 
of intensive research aimed at determining the feasibility of the survey and testing 
alternative methods for conducting the survey (NCHS, 1988). There has not been an 
extensive independent effort to validate the instruments used in the NAMCS surveys. 
Since the beginning of the surveys' deployment, there have been only a few studies that 
have examined the validity of the questionnaires used in NAMCS. Gilchrist et al. (2004) 
compared the NAMCS measurement approach with direct observation of outpatient 
visits, including office visits of 549 patients visiting 30 family physicians. As observed 
by trained research nurses, the visits were compared with data reported by physicians 
during the 1993 NAMCS survey deployment. While there was generally a good 
concordance between the NAMCS method and direct observation method for reports of 
procedures and examinations (including screening procedures), this was not the case for 
health behavior counseling. The result showed that reports from NAMCS may be more 
accurate for procedures and examination than for health behavior counseling. However, 
since its inception, the NAMCS has been a source of good data to describe U.S. primary 
care. There is evidence that the method of survey used is well established and provides 
nationally representative information on physician office visits (NCHS, n.d.-a). 
While most of the surveys were completed either through a paper instrument or 
electronically through the web-based instrument, it is important to note that three 
different methods were used in collecting the data; namely, through a self-administered 
web-based instrument completed electronically, a paper instrument that was self-
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administered and subsequently returned via mail, and the use of a computer-assisted 
telephone interview. The physicians selected in the sample were initially contacted by 
mail, in which a brief description of the survey was conveyed, and they were asked for 
their participation. In the next phase, field representatives contact the physicians by a 
phone call to set up an appointment for an in-office visit. At the in-office stage, the 
survey is explained more extensively, and approval to participate in the survey sought. 
For the physicians that agree to participate, a week is randomly assigned for the team to 
complete the survey, after which the physician mail the finished survey to the field 
representative. Data are collected using the patient log and the patient record.   
Data Analysis Plan 
This study's data source was the NAMCS, a national probability sample survey of 
visits to office-based physicians and community health centers conducted by the NCHS. 
IRB approval was sought and received before analyzing the dataset. The primary 
outcome variable was depression screening (yes/no). Independent variables that were 
explored include consultation with a mental health provider, time spent with the 
physician, gender, age, and race of patient, and physician specialty. Each of the 
independent variables were examined to determine if they served as predictors of 
depression screening in cancer patients during regular office visits with a physician. 
SPSS 25 was the statistical package that was used for all data analyses. The 
means or the relative frequencies or proportions and the standard errors (SE) of the 
independent variables were reported. To test whether the independent variables can 
predict the dependent variable, I performed a logistic regression analysis. The logistic 
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regression is the appropriate regression analysis to perform to determine or describe the 
relationship between a qualitative dependent variable that takes the form of a 
dichotomous variable and an independent variable. It can compute the odds ratio in the 
context of greater than one exploratory variable (Sperandei, 2014). Its use of a binomial 
response variable represents one of the main differences between it and multiple linear 
regression. In this study, the dependent variable were dichotomized, while the 
independent variables included both categorical variables such as gender and race, and 
continuous variables such as age. This approach aligns well with analyzing the dataset 
using logistic regression. Where appropriate, I presented the odds ratios (ORs), 95% 
confidence intervals (CIs), and the P values. Statistical significance was set at p<0.05. As 
part of the strategy to emphasize any signals in the data while excluding all potential 
"noise," I conducted data preparation to include recoding, assessing for variable 
reconstruction, and handling missing data (Kang, 2013).  
Coding of Responses 
 All the responses from the NAMCS dataset in SPSS were coded appropriately to 
fit logistic regression analysis. All dichotomous variables were assigned a code of 0 and 
1. For example, the value “0” was used to code for a “no” or similar response, while the 
value “1” was assigned to all responses that are “yes” or similar. For continuous 
independent variables, higher value represents more of the variable of interest.     
Missing Data 
My approach to handing missing data is described next. The tendency for 
introducing bias to subsequent statistical analyses when the missing data are greater than 
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10% is valid (Bennett, 2011). I explored all the main variables that were included in the 
analysis for missing data and logical inconsistencies. The skip pattern and section flow 
were examined in order to check for structural missing versus missing due to “refusal” or 
“don’t know” responses. The mean replacement method or the median replacement 
method in SPSS were used for missing data. When non-response occurs at an individual 
level, I made a decision on whether the data will be used or excluded.  
The Data Dictionary 
The data dictionary is discussed in this section for the purpose of defining the 
scope and characteristics of data elements used for analysis, and applicable rules that 
govern their application. Some examples of variables that are contained in the data 











width Column description Measure 
DEPRN Numeric  1 Does patient now have: 
Depression 
Unknown  
DEPRESS  Numeric 1 Depression screening Unknown 
CANCER Numeric 1 Does patient now have: 
Cancer 
Unknown 
Age Numeric 3 Patient age in years Unknown 
SEX Numeric 1 Patient sex Unknown 
MHP Numeric 1 Mental health provider 
seen 
Unknown 
TIMEMD Numeric 3 Time spent with physician 
in minutes 
Unknown 
RACER Numeric 1 Patient race—imputed Unknown 
SPECR Numeric 2 Physician specialty—14 
groups 
Unknown 
REGIONOFF Numeric 1 Region where majority of 







Research Questions and Hypotheses 
RQ1.  Is there an association between consultation with a mental health provider 
and screening for depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between consultation with a mental health provider and screening 
for depression among patients with a diagnosis of cancer.  
Alternative hypothesis (HA): There is a statistically significant association 
between consultation with a mental health provider and screening 
for depression among patients with a diagnosis of cancer. 
RQ2.  Is there an association between time spent with the physician and 
screening for depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between time spent with the physician and screening for 
depression among patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between time spent with the physician and screening for 
depression among patients with a diagnosis of cancer. 
RQ3.  Is there an association between gender and screening for depression 
among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between gender and screening for depression among patients with 
a diagnosis of cancer. 
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Alternative hypothesis (HA): There is a statistically significant association 
between gender and screening for depression among patients with 
a diagnosis of cancer. 
RQ4.  Is there an association between age and screening for depression among 
patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between age and screening for depression among patients with a 
diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant 
association between age and screening for depression among 
patients with a diagnosis of cancer.  
RQ5.  Is there an association between race and screening for depression among 
patients with a diagnosis of cancer?  
Null hypothesis (H0): There is no statistically significant association 
between race and screening for depression among patients with a 
diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between race and screening for depression among patients with a 
diagnosis of cancer. 
RQ6.  Is there an association between physician specialty and screening for 
depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
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between physician specialty and screening for depression among 
patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between physician specialty and screening for depression among 
patients with a diagnosis of cancer. 
Threats to Validity 
It is worth noting some potential threats to validity, both internal and external, 
related to this study. Internal and external validity are indicative of the instruments' 
properties, including questionnaires or surveys, and the population selected and used to 
collect data. Both concepts generally refer to a lack of systematic error.  A pictorial 
representation of the concept of study validity is depicted in Figure 2. 
Figure 2 
 
Schematic Representation of Validity 
 
Internal Validity 
The avoidance of major methodological problems and studies free from biases are 
the hallmarks of research with high internal validity. 
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Selection bias: The NAMCS uses a sophisticated, well-planned, three-stage, 
stratified cluster design in selecting participating respondents. For example, in the first 
stage, the primary sampling unit is selected with a probability proportional to population 
size and consists of identifying the county or group of counties of interest. The second 
stage is selected based on a probability inversely proportional to the number of 
physicians in the primary sampling unit. The third stage is selected based on the visits to 
a physician’s office. The three-stage, stratified cluster design ensures that there is no 
selection bias in terms of selecting participants for the survey. Also, while the sampling 
plan does not necessarily guarantee that all physicians and physician visits are sampled, it 
does ensure a reasonable representation.  
External Validity 
The ability to apply the results obtained from this study to a population broader 
than the one used in the study is referred to as external validity or generalizability (Patino 
& Ferreira, 2018). Therefore, it is crucial to consider the extent to which the respondents 
studied are representative of the more general population. Typically, this is done by 
characterizing and comparing those who did not participate in the study with those who 
did participate to identify any differences.  
For the study, I analyzed secondary data from the NAMCS dataset, which has an 
intricate survey design. Ward (2018) extensively demonstrated the impact of using 
inappropriate methods of estimation, known as an analytic error, in analyzing survey data 
from a complex survey design such as the NAMCS dataset and its effect on the 
generalizability of results. Specific examples include not applying data weights, 
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overlooking the foundational complexity of survey design, and deficiently subsetting data 
during subpopulation analysis. A proper understanding of the survey data and the use of 
the appropriate estimation techniques will go a long way as part of the strategies to 
mitigate the problem.   
Ethical Procedure 
The secondary dataset used in the study is from NAMCS, which is a freely 
available public dataset. The survey is administered by the NCHS, which is legally 
responsible for ensuring the confidentiality of all responses. This includes all potential 
data collected that may result in a physician or hospital being de-identified. Therefore, all 
information released publicly and used for research does not include any provider or 
patient identifying information. The survey data generally describes the characteristics of 
visits to ambulatory care services and may consist of data elements such as patient 
demographic characteristics, patients’ condition most often treated, and the diagnostic 
procedures and treatment that was given. Researchers intending to use NAMCS are 
expected to comply with data use restrictions to ensure that all information obtained from 
the dataset are used only for statistical analysis or reporting purposes. The data use 
restrictions agreement is available at 
https://www.cdc.gov/nchs/data_access/restrictions.htm. Therefore, the following efforts 
were made to ensure the confidentiality of individuals and establishments included in the 
dataset: 
 All datasets downloaded from NCHS were used for statistical analysis only. 
 No attempt was made to identify respondents included in the dataset. 
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 The dataset was not linked with individually identifiable data from other 
NCHS or non-NCHS datasets. 
 I did not engage in any activity with the intention of re-identifying individuals 
and establishments included in the dataset.  
Furthermore, the Walden university Internal Review Board (IRB) is tasked with 
ensuring that all research conducted in the University follows the Walden University’s 
ethical standards and U.S. federal regulations. Prior to the analysis of the secondary data, 
approval was obtained from the Walden University IRB. In case there is a need for a third 
party to review the dataset, I ensured they were trained in human subject research and 
Health Insurance Portability and Accountability Act (HIPAA) regulations before giving 
them access to the dataset. Any deviation to the research plan was planned to be promptly 
reported to the Walden University IRB. 
Summary 
In this chapter, I discussed extensively the research design. The variables that will 
be used were discussed concisely. A thorough review of the methodology, including the 
population, sampling, and sampling procedures, was presented. The sampling frame, 
including the eligibility criteria, as well as the power analysis, were highlighted. The 
instrumentation and operationalization of the survey to be used were also discussed. 
Finally, I transitioned to discussions related to validity threats and ethical procedures 
involved in the conduct of the research. In Chapter four, I present the results of the 
analysis of the secondary dataset. 
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Chapter 4: Results 
Introduction 
In this chapter, I summarize the results of the analyses performed. The logistic 
regression was used to determine whether there was any predictive association between 
the independent and dependent variables. Specifically, the study used the logistic 
regression to explore whether consultation with a mental health provider; time spent with 
the physician; patient gender, age, and race; and physician specialty were predictors of 
depression screening among patients with cancer attending ambulatory healthcare 
settings in the United States. To further investigate the effects of other potential 
predictors, additional post hoc analyses were conducted, and results are presented in this 
section.  
The purpose of this research was to determine and evaluate the predictors of 
depression screening among cancer patients in ambulatory care settings in the United 
States. This work contributes to the body of literature by increasing knowledge about 
determinants of depression screening among cancer patients related to crucial patient and 
physician characteristics. The study may also stimulate new approaches to recognizing 
and managing patients with comorbid conditions and informing public debates, policy-
making strategies, and screening guidelines. 
Research Questions and Hypotheses 
RQ1.  Is there an association between consultation with a mental health provider 
and screening for depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
70 
 
between consultation with a mental health provider and screening 
for depression among patients with a diagnosis of cancer.  
Alternative hypothesis (HA): There is a statistically significant association 
between consultation with a mental health provider and screening 
for depression among patients with a diagnosis of cancer. 
RQ2.  Is there an association between time spent with the physician and 
screening for depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between time spent with the physician and screening for 
depression among patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between time spent with the physician and screening for 
depression among patients with a diagnosis of cancer. 
RQ3.  Is there an association between gender and screening for depression 
among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between gender and screening for depression among patients with 
a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between gender and screening for depression among patients with 
a diagnosis of cancer. 
RQ4.  Is there an association between age and screening for depression among 
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patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between age and screening for depression among patients with a 
diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant 
association between age and screening for depression among 
patients with a diagnosis of cancer.  
RQ5.  Is there an association between race and screening for depression among 
patients with a diagnosis of cancer?  
Null hypothesis (H0): There is no statistically significant association 
between race and screening for depression among patients with a 
diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between race and screening for depression among patients with a 
diagnosis of cancer. 
RQ6.  Is there an association between physician specialty and screening for 
depression among patients with a diagnosis of cancer? 
Null hypothesis (H0): There is no statistically significant association 
between physician specialty and screening for depression among 
patients with a diagnosis of cancer. 
Alternative hypothesis (HA): There is a statistically significant association 
between physician specialty and screening for depression among 
72 
 
patients with a diagnosis of cancer. 
Data from the NAMCS comprising a national probability sample of visits to the 
emergency and outpatient departments of noninstitutional general and short-stay hospitals 
were accessed and analyzed to answer the research questions. The NAMCS consists of  
nationally representative data about outpatient practice in the United States. In this 
chapter, I present the results of the statistical analysis of the NACMS secondary dataset 
comprising merged datasets from 2014 through 2016. In the subsequent sections, I 
describe both the descriptive and inferential analyses. The chapter concludes with a 
summary, including a transitional summary that leads to this project’s final chapter. 
Results 
The 2014–2016 NAMCS datasets included 87,207 ambulatory care visits. A total 
of 7,146 visits by patients age 12 years and above who were diagnosed with cancer met 
the study inclusion criteria. Depression was reported at 9% of visits. Depression 
screening occurred during 3.8% of the community-based physician practice visits. Key 
predictor characteristics were summarized by categorical and continuous variables. 
Summaries included mean, standard deviation, minimum and maximum for continuous 
variables, and counts/frequencies and percentages for categorical variables. Information 
about the categorical variables for the population is provided in Tables 1–5, and 
information about the continuous variables is provided in Table 6. 
The age variable was subdivided into five categories: (a) 12-22 years, (b) 23-42 
years, (c) 43-62 years, (d) 63-72 years, and (e) 73 years and older (Table 2). Physician 
visits involved patients who were predominantly 73 years and older (39.3%). Patients in 
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the age groups 12-22, 23-42, 43-62, and 63-72 accounted for 30 (0.4%), 331 (4.6%), 
1,823 (25.5%), and 2,154 (30.1%) physician visits, respectively. Figure 3 shows the 
clustered bar percentage of depression screening by age group. Patients in the age groups 
63-72 and 73 and older were more likely to be screened for depression during physician 
office visits.  
Table 2 
Frequencies and Percentages of Patient Visits by Patient Age Group 
         Age group (years) Frequency (n) Percent (%) 
  
12-22 30 0.4 
23-42 331 4.6 
43-62 1823 25.5 
63-72 2154 30.1 
73 and older 2808 39.3 








In terms of gender, more physician visits involved male patients, accounting for 
3,641 (51%) visits (Table 3). The association between gender and depression screening 
was examined using the clustered bar chart in Figure 4, which shows that only 1.69% of 
male patient visits included screening for depression, while 2.14% of female patient visits 
included depression screening.   
Table 3 
 
Frequencies and Percentages of Patient Visits by Patient Gender 
Gender Frequency Percent 
Male 3,641 51.0 
Female 3,505 49.0 









Table 4 shows the frequencies and percentages of the racial/ethnic group 
categories. The race variable was subdivided into four categories: (a) Non-Hispanic 
White, (b) Non-Hispanic Black, (c) Hispanic, and (d) Non-Hispanic Other. Physician 
visits involved patients who were predominantly Non-Hispanic White, accounting for 
6,201 (86.8%) visits. Physician visits were somewhat comparable for the other 
racial/ethnic groups and accounted for 434 (6.1%), 352 (4.9%), and 159 (2.2%) for Non-
Hispanic Blacks, Hispanics, and Non-Hispanic Other, respectively. Association between 
racial/ethnic groups and depression screening was examined using a clustered bar chart. 
Similar to Table 4, Figure 5 shows that most physician visits that included a depression 
screening occurred among Non-Hispanic Whites (3.29%), compared to 0.20%, 0.27%, 
and 0.08% seen in the categories Non-Hispanic Black, Hispanic, and Non-Hispanic 
Other, respectively.   
Table 4 
 
Frequencies and Percentages of Patient Visits by Patient Race/Ethnicity  
Ethnic groups/total Frequency Percent 
Non-Hispanic White 6,201 86.8 
Non-Hispanic Black 434 6.1 
Hispanic 352 4.9 
Non-Hispanic Other 159 2.2 







Clustered Bar Percent of Depression Screening by Race/Ethnicity 
 
Furthermore, most physician visits, accounting for 1,816 (25.4%), were to 
physicians identified as having other specialties. Visits to dermatologists, urologists, and 
family physicians accounted for 1,146 (16.0%), 1,084 (15.2%), and 565 (7.9%), 
respectively, as shown in Table 5. The association between physician specialty and 
depression screening was also examined using a clustered bar chart. Figure 6 shows that 
depression screening was completed more among physicians with other specialties 







Frequencies and Percentages of Patient Visits by Physician Specialty 
 Frequency Percent 
General/family practice 565 7.9 
Internal medicine 423 5.9 
Pediatrics 25 .3 
General surgery 508 7.1 
Obstetrics and gynecology 168 2.4 
Orthopedic surgery 246 3.4 
Cardiovascular diseases 251 3.5 
Dermatology 1146 16.0 
Urology 1084 15.2 
Psychiatry 51 .7 
Neurology 132 1.8 
Ophthalmology 366 5.1 
Otolaryngology 365 5.1 
Other specialties 1816 25.4 







Clustered Bar Percent of Depression Screening by Physician Specialty 
 
In terms of ambulatory visits involving consultation with a mental health 
provider, physician visits involved predominantly patients who did not consult with a 
mental health provider, accounting for 7,126 (99.7%) visits, as shown in Table 6. The 
association between consultation with a mental health provider and the outcome variable 
was examined using a clustered bar chart. Figure 7 shows that within the group that 
consulted with a mental health provider, only 0.03% of visits included screening for 
depression. In comparison, 3.81% of physician visits had depression screening among 





Frequencies and Percentages of Patient Visits by Mental Health Provider Seen 
Mental health provider seen Frequency Percent 
  
No 7,126 99.7 
Yes 20 .3 
Total 7,146 100.0 
 
Figure 7 






Univariate Descriptive Statistics for Continuous Variables 
The continuous variable was summarized by tabulations of n, mean, range, 
standard deviation, maximum, and minimum. The only continuous variable included in 
the analysis is “the time spent with physician.” The variable was measured in minutes, 
with the minimum and maximum time spent being zero and 90 minutes, respectively. The 
mean time spent with a physician was 23.23 minutes with a standard deviation of 14.214. 












Time spent with 
physician in minutes 
7,146 90 0 90 23.23 14.214 
Valid N (listwise) 7,146      
 
Univariate Logistic Regression  
Logistic regression was used to assess how well the set of predictor variables 
predicted or explained the categorical dependent variable of screening for depression 
(yes/no). The specific individual effect of each of the predictor variables on the outcome 
variable and the amount of variance explained by each predictor variable was explored. 
Simple logistic regression was performed for each of the research questions.  
Research Question 1 
The first research question explored whether there is an association between 
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consultation with a mental health provider and screening for depression among patients 
with a diagnosis of cancer. Simple logistic regression was performed to assess the impact 
of consultation with a mental health provider among patients with a cancer diagnosis on 
the likelihood that they will have a depression screening  during that visit. Variables 
with p-values less than 0.05 represent those that contributed significantly to the predictive 
ability of the model. The full model containing the predictor (i.e., consultation with a 
mental health provider) was not statistically significant, χ² (1, N=7146) = 1.455, p=0.228, 
indicating that the model was not significantly better than the baseline model (i.e., the 
result of the analysis with only the dependent variable). The model explained between 
0.0% (Cox and Snell R square) and 0.001% (Nagelkerke R squared) of the variance in 
depression screening and correctly classified 96.2% of cases. Table 8 shows that 
consultation with a mental health provider failed to make a unique, statistically 
significant contribution to the model. The odds ratio was 2.8. This implies that patients 
who consulted with a mental health provider during an ambulatory visit were almost 
three times as likely to report screening for depression as those who did not consult a 
mental health provider. However, this was not statistically significant (p=0.169). This is 
evidenced by a 95% CI that ranged between 0.646 and 12.127. Based on the findings, I 





Logistic Regression: Consultation With a Mental Health Provider as a Predictor of 
Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 





provider seen (1) 
1.030 .748 1.895 1 .169 2.800 .646 12.127 
Constant -3.227 .062 2724.002 1 .000 .040   
a Variable(s) entered on Step 1: Mental health provider seen. 
 
Research Question 2 
The second research question explored whether there is an association between 
time spent with the physician and screening for depression among patients with a 
diagnosis of cancer. Simple logistic regression was performed to assess the impact of 
time spent with the physician among patients diagnosed with cancer on the likelihood 
that they had a screening for depression completed during that physician's office visit. 
The full model containing time spent with the physician as a predictor was not 
statistically significant, χ² (1, N=7146) = 2.061, p=0.151, indicating that the model was 
not significantly better than the baseline model (i.e., the result of the analysis with only 
the dependent variable). The model as a whole explained between 0.0% (Cox and Snell R 
square) and 0.00% (Nagelkerke R squared) of the variance in depression screening and 
correctly classified 92.2% of cases. Table 9 shows that "time spent with the physician" 
failed to make a unique statistically significant contribution to the model. The odds ratio 
was 1.006. This implies that for every unit increase in time spent with a physician during 
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an ambulatory visit, the odds of screening for depression increased by 0.6%. This 
relationship was not statistically significant, as evidenced by a 95% CI that ranged 
between 0.998 and 1.014. Based on the findings, I did not reject the null hypothesis. 
Table 9 
 
Logistic Regression: Time Spent With Physician as a Predictor of Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 




Time spent with 
physician in minutes 
.006 .004 2.177 1 .140 1.006 .998 1.014 
Constant -3.362 .115 850.706 1 .000 .035   
a Variable(s) entered on Step 1: Time spent with physician in minutes. 
 
Research Question 3 
The third research question explored whether there is an association between 
patient gender and screening for depression among patients with a diagnosis of cancer. 
Simple logistic regression was performed to assess the impact of gender among patients 
diagnosed with cancer on the likelihood that they were screened for depression. The full 
model containing gender as the predictor was statistically significant χ² (1, N=7146) = 
5.265, p = 0.02, indicating that the model could distinguish between patients who had a 
screening for depression and those that did not. The model explained between 0.1% (Cox 
and Snell R square) and 0.3% (Nagelkerke R squared) of the variance in depression 
screening and correctly classified 96.2% of cases. As shown in Table 10, gender made a 
unique, statistically significant contribution to the model. The odds ratio of 1.328 implies 
that female cancer patients were 1.3 times as likely to report screening for depression as 
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their male counterparts. This finding was statistically significant (p = 0.02, odds 
ratio=1.328, CI=1.041-1.693). Based on the findings, the null hypothesis was rejected.  
Table 10 
 
Logistic Regression: Gender as a Predictor of Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 




Patient sex(1) .284 .124 5.227 1 .022 1.328 1.041 1.693 
Constant -3.370 .092 1328.853 1 .000 .034   
a Variable(s) entered on Step 1: Patient sex. 
 
Research Question 4 
The fourth research question explored whether there was an association between 
patient age and screening for depression among patients with a diagnosis of cancer. 
Simple logistic regression was performed to assess the impact of patient age among 
patients with a cancer diagnosis on the likelihood of being provided with screening for 
depression. The full model containing age as a predictor was not statistically significant 
χ² (4, N=7146) = 3.789, p = 0.435, indicating that the model was not significantly better 
than the baseline model (i.e., the result of the analysis with only the dependent variable). 
The model explained only between 0.1% (Cox and Snell R square) and 0.2% (Nagelkerke 
R squared) of the variance in depression screening and correctly classified 96.2% of 
cases. Table 11 shows that none of the age groups were significant predictors of 






Logistic Regression Showing Age as a Predictor of Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 




Age group   3.862 4 .425    
Age Group(1) .387 1.049 .136 1 .712 1.473 .189 11.509 
Age Group(2) .086 1.025 .007 1 .933 1.089 .146 8.119 
Age Group(3) .280 1.023 .075 1 .784 1.323 .178 9.819 
Age Group(4) .037 1.022 .001 1 .971 1.038 .140 7.696 
Constant -3.367 1.017 10.961 1 .001 .034   
a Variable(s) entered on Step 1: Age group. 
 
Research Question 5 
The fifth research question explored whether there was an association between 
patient race and screening for depression among patients with a diagnosis of cancer. 
Simple logistic regression was performed to assess the impact of race among patients 
with a cancer diagnosis on the likelihood of being provided with screening for 
depression. The full model containing race as a predictor was not statistically significant 
χ² (3, N=7146) = 2.574, p = 0.462, indicating that the model was not significantly better 
than the baseline model (i.e., the result of the analysis with only the dependent variable). 
The model explained between 0.0% (Cox and Snell R square) and 0.01% (Nagelkerke R 
squared) of the variance in depression screening and correctly classified 96.2% of cases. 
Table 12 shows that none of the racial groups were significant predictors of screening for 






Logistic Regression Showing Race as a Predictor of Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 






  2.773 3 .428    
Race/ethnicity—
Imputed(1) 
-.167 .280 .356 1 .551 .846 .489 1.464 
Race/ethnicity—
Imputed(2) 
.371 .245 2.286 1 .131 1.449 .896 2.342 
Race/ethnicity—
Imputed(3) 
-.004 .421 .000 1 .992 .996 .436 2.274 
Constant -3.234 .067 2365.024 1 .000 .039   
a Variable(s) entered on Step 1: Race/ethnicity—Imputed. 
 
Research Question 6 
The sixth research question explored whether there was an association between 
physician specialty and screening for depression among patients with a diagnosis of 
cancer. Simple logistic regression was performed to assess the impact of physician 
specialty among patients with a cancer diagnosis on the likelihood of being screened for 
depression. The model contained one predictor variable (physician specialty). The full 
model containing the predictor variable was statistically significant χ² (13, N=7146) = 
161.273, p < .001, indicating that the model was able to distinguish between patients who 
had a screening for depression and those that did not. The model explained between 2.2% 
(Cox and Snell R square) and 8.0% (Nagelkerke R squared) of the variance in depression 
screening and correctly classified 96.2% of cases. Table 13 shows that physician 
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specialty was significantly associated with receipt of depression screening. The odds of 
receiving screening for depression were higher among patients that saw their primary 
care physicians than among patients that saw their physicians in general surgery, 
orthopedic surgery, cardiovascular disease, dermatology, urology, ophthalmology, and 






Logistic Regression Showing Physician Specialty as a Predictor of Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 









.025 .231 .012 1 .914 1.025 .651 1.614 
Physician specialty—14 
groups (pediatrics) 
-.043 .753 .003 1 .955 .958 .219 4.191 
Physician specialty—14 
groups (general surgery) 
-1.093 .303 12.990 1 .000 .335 .185 .607 
Physician specialty—14 
groups (obstetrics and 
gynecology) 








-1.496 .477 9.848 1 .002 .224 .088 .570 
Physician specialty—14 
groups (dermatology) 
-2.847 .437 42.498 1 .000 .058 .025 .137 
Physician specialty—14 
groups (urology) 
-1.268 .247 26.256 1 .000 .282 .173 .457 
Physician specialty—14 
groups (psychiatry) 
.718 .414 3.007 1 .083 2.050 .911 4.617 
Physician specialty—14 
groups (neurology) 
-.215 .377 .325 1 .569 .806 .385 1.690 
Physician specialty—14 
groups (ophthalmology) 
-2.804 .725 14.951 1 .000 .061 .015 .251 
Physician specialty—14 
groups (otolaryngology) 




groups (other specialties) 
-.453 .184 6.065 1 .014 .635 .443 .912 
Constant -2.400 .152 248.164 1 .000 .091   
a Variable(s) entered on Step 1: Physician specialty—14 groups. 
 
Additional Analyses 
Additional analyses were performed to characterize and explore potential 
predictors of depression screening among patients diagnosed with cancer. Another 
rationale for including these analyses was based on the increasing evidence that 
physicians' region of practice appeared to contribute as an important determinant of 
health care services provision (Bhattacharjee et al., 2018; Harrison et al., 2010). These 
analyses, though not defined a priori, are included in this section. Specifically, an 
additional analysis was performed to investigate the relationship between the region 
where physicians’  visits occurred, and the probability of screening for depression. The 
variable consisted of four categories, including Northeast, Midwest, South, and West. 
Table 14 depicts the frequencies and percentages of the regions where most physicians’ 
sampled visits occurred. Most visits occurred in the Midwest and South, accounting for 
30.8% and 31.9%, respectively, of the total visits.  
Table 14 
 
Frequencies and Percentages of Geographic Region 
Geographic region Frequency Percent 
 
Northeast 1014 14.2 
Midwest 2199 30.8 
South 2278 31.9 
West 1655 23.2 
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Total 7146 100.0 
 
Simple logistic regression was performed to assess whether region was a predictor 
of depression screening. The full model containing region as a predictor was statistically 
significant χ² (3, N=7146) = 11.533, p = 0.009, indicating that the model was able to 
distinguish between patients who received and those who did not receive screening for 
depression. The model explained between 0.2% (Cox and Snell R square) and 0.6% 
(Nagelkerke R squared) of the variance in depression screening and correctly classified 
96.2% of cases. Table 15 shows that cancer patients who had physician visits in the 
Northeast region were approximately twice as likely to be screened for depression as 
those having visits in the Midwest (OR=2.074, CI=1.311-3.283, P=.002), 1.8 times as 
likely to be screened for depression as those having visits in the West (OR=1.818, 
CI=1.125-2.939, P=.002), and 1.6 times as likely to be screened for depression as those 
having visits in the South.   
Table 15 
 
Logistic Regression Showing Region as a Predictor of Depression Screening 
 
B SE Wald df Sig. 
Odds 
ratio 




Region where majority 
of physician's sampled 
visits occurred 
  10.325 3 .016    
Region where  
physicians’ visits 
occurred (Midwest) 
.730 .234 9.702 1 .002 2.074 1.311 3.283 
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Region where  
physician's visits 
occurred (South) 
.488 .239 4.181 1 .041 1.629 1.020 2.601 
Region where  
physician's visits 
occurred (West) 
.598 .245 5.950 1 .015 1.818 1.125 2.939 
Constant -3.763 .211 318.334 1 .000 .023   
a Variable(s) entered on Step 1: Region where majority of physician's sampled visits occurred. 
Additionally, multivariate logistic regression was performed. The findings were 
consistent with the univariate analyses in which physician specialty and geographical 
region where physician visits occurred were significantly associated with receipt of 
depression screening. However, when the other variables were controlled for, gender, 
which was a statistically significant predictor of depression screening among cancer 
patients on its own, was no longer significant, implying a potential confounder interaction 






Multivariate Logistic Regression Predicting Likelihood of Receipt of Depression 
 
B SE Wald df Sig. 
Odds 
ratio 




Mental health provider seen (1) .064 .781 .007 1 .934 1.066 .231 4.931 
Time spent with physician in minutes .000 .004 .007 1 .933 1.000 .992 1.009 
Patient sex (1) .126 .134 .878 1 .349 1.134 .872 1.476 
Age group   3.382 4 .496    
Age Group (1) .546 1.102 .245 1 .620 1.726 .199 14.956 
Age Group (2) .295 1.079 .075 1 .785 1.343 .162 11.140 
Age Group (3) .571 1.077 .281 1 .596 1.770 .214 14.628 
Age Group (4) .386 1.078 .128 1 .720 1.471 .178 12.170 
Race/ethnicity—Imputed   3.921 3 .270    
Race/ethnicity—Imputed (1) -.318 .285 1.244 1 .265 .728 .416 1.272 
Race/ethnicity—Imputed (2) .382 .253 2.287 1 .130 1.466 .893 2.406 
Race/ethnicity—Imputed (3) -.126 .429 .087 1 .768 .881 .380 2.042 
Physician specialty—14 groups   111.838 13 .000    
Physician specialty—14 groups (1) .110 .235 .218 1 .641 1.116 .705 1.767 
Physician specialty—14 groups (2) .099 .790 .016 1 .900 1.105 .235 5.197 
Physician specialty—14 groups (3) -1.115 .306 13.296 1 .000 .328 .180 .597 
Physician specialty—14 groups (4) -.458 .385 1.413 1 .235 .633 .298 1.346 
Physician specialty—14 groups (5) -1.626 .528 9.486 1 .002 .197 .070 .554 
Physician specialty—14 groups (6) -1.457 .478 9.288 1 .002 .233 .091 .594 
Physician specialty—14 groups (7) -2.831 .438 41.867 1 .000 .059 .025 .139 
Physician specialty—14 groups (8) -1.197 .254 22.177 1 .000 .302 .184 .497 
Physician specialty—14 groups (9) .822 .437 3.543 1 .060 2.275 .967 5.352 
Physician specialty—14 groups (10) -.203 .382 .281 1 .596 .817 .386 1.728 
Physician specialty - 14 groups(11) -2.779 .726 14.642 1 .000 .062 .015 .258 
Physician specialty—14 groups (12) -1.833 .477 14.781 1 .000 .160 .063 .407 
Physician specialty—14 groups (13) -.429 .187 5.274 1 .022 .651 .452 .939 
Region where majority of physician's 
sampled visits occurred 
  12.084 3 .007    
Region where majority of physician's 
sampled visits occurred (1) 
.779 .239 10.599 1 .001 2.179 1.363 3.483 
Region where majority of physician's 
sampled visits occurred (2) 




B SE Wald df Sig. 
Odds 
ratio 
95.0% CI for odds ratio 
Lower Upper 
Region where majority of physician's 
sampled visits occurred (3) 
.662 .249 7.076 1 .008 1.939 1.190 3.160 
Constant -3.509 1.121 9.804 1 .002 .030   
a Variable(s) entered on Step 1: Mental health provider seen, Time spent with physician in minutes, Patient sex, Age group, 
Race/ethnicity—imputed,  Physician specialty, Region where majority of physician's sampled visits occurred. 
 
Summary 
Chapter 4 used the NAMCS dataset, which comprises a national probability 
sample of visits to the emergency and outpatient departments of noninstitutional general 
and short-stay hospitals, to evaluate the predictors of depression screening in patients 
diagnosed with cancer. The predictors included consultation with a mental health 
professional, time spent with the physician, patient gender, age, and race, and physician 
specialty. Even though the geographical region was not specified a priori as a predictor, 
it was nevertheless included in the final analyses. It was included to characterize and 
explore other potential predictors of depression screening among patients diagnosed with 
cancer.    
The results of the data analyses were presented in this chapter.  Both univariate 
and multivariate logistic regression were performed to characterize the predictors and 
appropriately analyze the data. The odds ratios, including the CI and statistical 
significance of the associations, were reported. Based on the simple logistic regression 
analyses, age, physician specialty, and geographical region of physician visits were found 
to be statistically significant predictors of receipt of depression screening among cancer 
patients attending ambulatory care settings. The results of the multivariate analysis were 
similar to those of the simple logistic regression analyses. However, when all the other 
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independent variables were controlled for in the model, the gender variable was no longer 
a statistically significant predictor of depression screening, thereby indicating a potential 
confounding effect.   
Chapter 5 will discuss the interpretation of the results and the strengths and 
limitations of the study. The results will be discussed in the context of the current 
knowledge in the discipline by comparing the findings in this study with those in the 
recent  literature . The chapter will end with recommendations for future research and the 




Chapter 5: Discussion 
Introduction 
Cancer occurring comorbidly with depression continues to be a significant public 
health problem (Pule et al., 2019). Despite improved cancer outcomes associated with 
prompt and adequate treatment of depression in cancer, studies have shown that 
depression is underrecognized and undertreated among cancer patients. Several 
guidelines have recommended that cancer patients be routinely screened for depression. 
Therefore, this research determined and evaluated the predictors of depression screening 
among cancer patients in ambulatory care settings in the United States. The study 
explored the factors that predict depression screening for cancer patients in ambulatory 
settings. Sociodemographic factors, such as age, gender, and race, and other variables, 
such as physician specialty, time spent with the physician, and consultation with a mental 
health provider, were explored as potential predictor variables. The outcome variable was 
depression screening (yes/no). The study used a quantitative approach with a cross-
sectional study design to determine if there were any relationships between the 
independent and dependent variables. Secondary data from the NAMCS, which 
comprises a national probability sample of visits to the emergency and outpatient 
departments of noninstitutional general and short-stay hospitals, were analyzed.  
The NAMCS data are designed to meet the need for objective, reliable 
information about the provision and use of ambulatory medical care services in the 
United States. The database is open to the public and easily accessed by going to a 
website. The data were collected using surveys that captured physician-patient encounters 
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or clinic visits. These encounters could have involved direct or personal interaction 
between a patient and his or her physician or clinic staff working under the direct 
supervision of a physician.  
This study was conducted to contribute to the body of literature on depression 
screening among cancer patients. My decision to conduct this study was based on the 
public health significance of depression occurring comorbidly with cancer. Increased 
knowledge of predictors of depression screening in cancer patients has the potential to 
translate to a higher rate of screening, thereby reducing underdiagnosis and 
undertreatment. 
Interpretation of the Findings 
This study is the first to explore the predictors of depression screening among 
cancer patients. Findings from this research show that out of the total 7,146 visits that 
met the inclusion criteria, 274 visits included depression screening. These data indicate 
that among patients with cancer attending ambulatory care clinics during the entire study 
period, approximately 3.8% of visits included depression screening. This shows that 
depression screening of cancer patients in the United States is not very common. Other 
key findings based on the simple logistic regression analyses in the current study were 
that gender, physician specialty, and the geographic region in which physician visits 
occurred were statistically significant predictors of receipt of depression screening among 
cancer patients attending ambulatory care settings. The result of the multivariate analysis 
was similar to the simple logistic regression. However, when the other independent 
variables were controlled for, the gender variable was no longer a statistically significant 
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predictor of depression screening, implying a potentially confounding effect. 
The finding of a low depression screening rate among cancer patients in the 
current study is similar to findings of previous studies that explored the rate of depression 
screening among adults in ambulatory care settings in the United States (Bhattacharjee et 
al., 2018; Harrison et al., 2010). Possible reasons for the low rate of depression screening 
seen in the current study may be related to the evolution of guidelines and 
recommendations for depression screening. There has been a highly contentious debate 
on depression screening over the last three decades. Earlier recommendations had argued 
against routine screening in the ambulatory care setting, with later updates in 2002 and 
2009 recommending screening adults for depression only when appropriate staff-assisted 
depression care supports are in place (USPSTF, 2002, 2009). Although the most recent 
updates to the USPSTF recommendations on depression screeing in 2016 omitted the 
requirement that screening only occur in the presence of enhanced services (Siu et al., 
2016), it is essential to note that the data analyzed in this study were 2014–2016 NAMCS 
data. It is therefore possible that the previous restrictive guideline could have affected the 
general rate of depression screening, which may explain the relatively low depression 
screening rate reported in the current study. 
Furthermore, uncertainty about the diagnosis of depression and subsequent 
treatment could have contributed to the low rate of depression screening reported in the 
current study. It is often challenging for physicians to differentiate between the “natural” 
unhappiness and anxiety that accompany terminal illness diagnoses such as cancer and 
pathological mood alterations. Complicating the uncertainty is the fact that it is not 
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unusual for some of the symptoms of both conditions to overlap. Over time, most 
healthcare providers dealing with comorbid conditions lose their self-efficacy about 
treating cancer patients with depression. They lose the belief that such treatments can 
make any difference in patient outcomes (Greenberg, 2004). Physicians often have 
limited time for extensive discussion with their patients about any ongoing emotional and 
psychological challenges. These limited interactions result in several missed 
opportunities to elicit depressive symptoms from patients and create the right conditions 
for physicians to avoid patients’ questions about emotions. Patients who are afraid of 
being stigmatized also might refuse to volunteer information about their emotional 
predicaments. The combination of a physician who refuses to “ask” and a patient who 
refuses to “tell” makes depression screening very unlikely (Maguire, 1985).   
Mental Health Provider 
Both the simple logistic regression and the multivariable analysis did not detect 
any significant predictive association between seeing a mental health provider during 
visits and screening for depression. Qualified mental health providers play a pivotal role 
in diagnosing depression and linking patients to treatment. Indeed, studies have shown 
that depressed patients prefer that a mental health provider rather than a primary care 
physician provide evidence-based treatment for their depression (Van Voorhees et al., 
2003). This implies that, contrary to this study's findings, one would expect that seeing a 
mental health provider during an ambulatory visit would be a predictor of receiving 
depression screening. One reason for the findings of the current study may be the low 
proportion of visits in which mental health providers were seen, representing only 0.3% 
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of the total visits included in the study. In essence, the result should not necessarily be 
interpreted as meaning that the mental health services offered by mental health providers 
are meaningless, but rather that there were insufficient visits with mental health providers 
to demonstrate any relationship. In the current study, out of the 7,146 visits included in 
the analysis, only 20 visits included visits to mental health providers. The 
disproportionately low number of visits with mental health providers may explain why 
there was no association between visits to a mental health provider and screening for 
depression. 
Time Spent With Physician 
Furthermore, time spent with the physician was not a significant predictor of 
depression screening. This may underscore the importance of differentiating between 
quality versus quantity of time spent with the physician. This finding implies that 
increasing the length of visits to a physician’s office does not necessarily substitute for a 
qualitative physician office visit. Complex and dynamic physician-patient interactions, 
including time spent gathering a patient’s history, establishing a relationship, and 
engaging in administrative work, contribute to the time that a physician spends with 
patients (Dugdale et al., 1999). Typically, the physician’s workload does not allow 
enough time to navigate all of these complex interactions. Therefore, even when the time 
for physician-patient interaction increases, there are multiple activities that may occur 
during this time, and screening for depression is not necessarily among them. 
Gender 
This study found that females were more likely to be screened for depression than 
100 
 
males in the simple logistic regression analysis. This was in keeping with a higher 
incidence of depression among females in the general population. However, some 
prevalence research studies on gender differences in cancer occurring comorbidly with 
depression have, for the most part, yielded conflicting results (Miaskowski, 2004). For 
example, some studies have found that the gender difference in the depression incidence 
rate among the general population is reversed among cancer patients, with depression 
occurring more in men, and men with cancer reporting more depression symptoms than 
women with cancer (Pudrovska, 2010). Other investigators have reported that depressed 
women are more likely than depressed men to present with psychiatric and medical 
comorbidity, including cancer (de Leeuw et al., 2001; Hopwood & Stephens, 2000; Sloan 
& Sandt, 2006). The finding that females demonstrated significantly higher odds of 
depression screening than their male counterparts is similar to previous studies 
(Bhattacharjee et al., 2018; Harrison et al., 2010). This variation may well imply that the 
lower prevalence rates of depression seen in male cancer patients may be driven by 
underdiagnosis due to a lower screening rate.   
This finding underscores the importance of driving awareness campaigns and 
educating male cancer patients about depression, screening for depression, and 
engagement in early treatment as appropriate. This is particularly important in that cancer 
has more adverse psychological implications for men than for women (Pudrovska, 2010). 
Physicians should also be aware of the need to actively pursue depression screening for 




Although studies have shown that depression tends to vary with age, this study 
showed that age did not significantly predict depression screening among cancer patients. 
The result showing that age was not a significant predictor of depression screening 
among cancer patients was the same for the multivariable analysis. While studies have 
shown that cancer and mental health comorbidities are associated with poorer outcomes, 
studies have also shown that the age of patients with comorbidities is not a driver of 
poorer outcomes and not a predictor of clinical response (Angstman et al., 2011). This 
may explain why age was not a significant predictor of depression screening among the 
patient population. If age is not related to patient outcome, then there may not be any 
motivation to screen patients for depression based on their age alone. 
Race 
Concerning the fifth research question, results showed that race was not a 
significant predictor of screening for depression among cancer patients. Based on the data 
analyzed, the total sample of those screened for depression across the different racial 
groups was small. Additionally, there was disproportionate representation of the different 
racial groups in the study, with non-Hispanic Whites heavily and disproportionately 
represented compared to the other racial groups. This may have been responsible for the 
nonsignificant association found in the data. 
Region 
The current study demonstrated that cancer patients who had physician visits in 
the Northeast region were more likely to be screened for depression than those having 
102 
 
physician visits in the other geographic regions of the United States. This finding is in 
keeping with previous research (Bhattacharjee et al., 2018; Harrison et al., 2010). This 
may be a result of disparities in the physician workforce across the country. Based on the 
current projection, the South and West regions are expected to continue to see more 
physician workforce shortages than the Northeast (Zhang et al., 2020). Other reasons for 
these findings may involve the geographic distribution of physicians across the four U.S. 
Census Bureau regions. Residents of metropolitan areas such as those of the Northeast 
have better geographic access to physicians, whereas residents of isolated rural counties 
have less access (Rosenthal et al., 2005). This research underscores the need to create 
enabling environments that can improve the awareness of depression screening, 
especially in regions outside the Northeast. 
Physician Specialty 
The current study showed that the odds of screening for depression were 
significantly higher during a visit to a primary care physician than to physicians of other 
specialties. Different guidelines recommend that the general adult population be screened 
for depression with the primary care physician designated as the primary focus for 
screening for depression. For example, the American College of Preventive Medicine 
(ACPM) emphasizes the primary care physician as the care provider to screen for 
depression. Specifically, the ACPM recommends that the primary care physician screen 
all adults for depression, and that there should be systems in place, either within the 
primary care setting itself or through collaborations with mental health professionals, to 
ensure the accurate diagnosis and treatment of depression (Nimalasuriya et al., 2009).  
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As a generalization, most patients with depression, including cancer patients with 
comorbid depression, will receive their depression care in the primary care setting. There 
is evidence that patients with comorbid depression are more likely to contact a primary 
care provider than providers in other specialties (Akincigil & Matthews, 2017). This 
study’s results go further to emphasize the pivotal role that primary care physicians play 
in ensuring prompt diagnosis and adequate follow-up treatment for cancer patients with 
depression. Lo and colleagues (2013) explored how depression affected health care 
service utilization in patients diagnosed with cancer. They reported that patients with 
depression were more likely to visit primary care physicians but less likely to visit 
oncologists than cancer patients without depression (Lo et al., 2013). Therefore, all 
efforts must be made to ensure that primary care physicians continue to have all they 
require to continue to provide depression screening for the cancer population. 
Limitations 
The current study had some limitations, and as a result, findings from this 
research work should be interpreted with caution. First, this study's cross-sectional design 
implies that both the predictors and the outcome variable were simultaneously assessed 
and does not allow for causal inference. Further, the fact that a patient was not screened 
for depression during a particular visit does not mean that the patient was not screened by 
some other means. Additionally, the dataset did not identify any specific depression 
screening type or procedure used by physicians. This makes it difficult to understand how 
the different physicians defined depression screening. The implication is that depression 
screening methods may have varied widely from one physician to another. While some 
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providers may have adopted a particular type of screening criteria, others may have used 
different screening criteria.  
Another limitation of the current study related to the NAMCS data is that 
depression screening was explored based on patient visits. It is quite possible that 
different estimates might have been derived if the predictors of depression screening had 
been explored using individual patients as the unit of analysis instead of physician visits. 
The relatively low proportion of some of the variables may mean that there were not 
enough data to demonstrate whether there was any effect. For example, the proportion of 
visits that included seeing a mental health provider was very low. While there was no 
significant relationship between seeing a mental health provider and depression 
screening, it is difficult to conclude that the services provided by the mental health 
providers were not clinically significant. Finally, given that secondary data were used, it 
is not possible to conveniently rule out potential data collection errors, data entry errors, 
and data reporting errors. 
Recommendations 
In the current study, I focused primarily on the predictors of depression screening 
among cancer patients. There were a number of reasons for this focus, including the 
dearth of literature in the field of predictors of depression screening among cancer 
patients, the public health significance of depression occurring comorbidly with cancer, 
and the potential that the knowledge of predictors of depression screening in cancer 
patients may translate to a higher rate of screening, thereby reducing underdiagnosis and 
undertreatment. As mentioned above, this study used a cross-sectional design, which 
105 
 
precludes the possibility of making any causal inference. Future research should use other 
study designs where patients are followed up until the desired outcome of interest is 
observed or not observed. This type of study design can better establish a causal 
relationship. The NAMCS dataset used in this research did not specify the strategy used 
for depression screening; therefore, future research should improve on this by defining 
and standardizing depression screening methods across all patients and physician visits. 
Future research should also use patients as the unit of analysis rather than physician 
visits. 
Furthermore, in the current study, I explored the predictors of depression 
screening among cancer patients in general. Potentially, different cancer types, including  
anatomic location and histology, may have different predictors for depression screening.. 
Therefore, future studies should seek to explore the predictors of depression screening in 
different cancer types.  
Implications 
The results of the current study can potentially influence positive social change at 
both the individual and organizational levels. The findings can also inform policy 
changes that can impact screening guidelines at the societal level. From the study, gender 
was a predictor of screening for depression among cancer patients, with females having a 
higher probability of being screened. This knowledge presents an opportunity for a 
targeted educational strategy among male cancer patients to increase the awareness of 
depression co-occurring with cancer and engage their physicians on the need to screen 
proactively.    
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Additionally, this research showed that a visit to a primary care physician is more 
likely to result in screening for depression among cancer patients compared to other 
physician specialists. This is in keeping with most guidelines for depression screening in 
which primary care physicians are the primary drivers of depression screening. While the 
current study can encourage the continuous provision of incentives to strengthen 
proactive screening for depression among cancer patients by primary care physicians, 
guidelines and policies can be updated to ensure proper training for other specialists to 
reduce the many missed opportunities for depression screening. Overall, the current study 
can contribute to society by stimulating new approaches to recognizing and managing 
patients with comorbid conditions and informing public debates, policy-making 
strategies, and screening guidelines.   
Conclusion 
The current study explored the predictors of depression screening among cancer 
patients in the ambulatory care setting in the United States. While depression screening is 
a crucial first step in diagnosing depression among cancer patients and connecting 
patients to the treatment they need, the current study found that the depression screening 
rate among cancer patients is extremely low in the U.S ambulatory care setting (3.8%). 
The current study found patient gender, physician specialty, and geographic region to be 
statistically significant predictors of depression screening among cancer patients. Based 
on these  findings, routine depression screening rates among cancer patients can be 
improved by targeting interventions, especially at male patients, and improving 
physicians' training so they can gain competence in screening for depression. The results 
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also suggest an opportunity for creating an enabling environment that can enhance the 
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